U.S. patent application number 15/285798 was filed with the patent office on 2017-01-26 for troponin and bnp based diagnosis of risk patients and cause of stroke.
The applicant listed for this patent is Roche Diagnostics Operations, Inc.. Invention is credited to Georg Hess, Andrea Horsch, Dietmar Zdunek.
Application Number | 20170023588 15/285798 |
Document ID | / |
Family ID | 47049159 |
Filed Date | 2017-01-26 |
United States Patent
Application |
20170023588 |
Kind Code |
A1 |
Hess; Georg ; et
al. |
January 26, 2017 |
TROPONIN AND BNP BASED DIAGNOSIS OF RISK PATIENTS AND CAUSE OF
STROKE
Abstract
Method for determination of whether a subject suffers from
intermittent atrial fibrillation based on the determination of the
amount of a Troponin T in a sample in a patient suffering from
atrial fibrillation using a binding assay. Kits and devices adapted
to carry out the methods are also provided.
Inventors: |
Hess; Georg; (Mainz, DE)
; Horsch; Andrea; (Luzern, CH) ; Zdunek;
Dietmar; (Tutzing, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Roche Diagnostics Operations, Inc. |
Indianapolis |
IN |
US |
|
|
Family ID: |
47049159 |
Appl. No.: |
15/285798 |
Filed: |
October 5, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14859616 |
Sep 21, 2015 |
|
|
|
15285798 |
|
|
|
|
14251803 |
Apr 14, 2014 |
|
|
|
14859616 |
|
|
|
|
PCT/EP2012/070553 |
Oct 17, 2012 |
|
|
|
14251803 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
G01N 33/6887 20130101;
G01N 33/6893 20130101; G01N 2333/47 20130101; G01N 2800/326
20130101; G01N 33/54306 20130101; G01N 2333/4712 20130101 |
International
Class: |
G01N 33/68 20060101
G01N033/68 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 17, 2011 |
EP |
11185421.2 |
Claims
1. A method of diagnosing intermittent atrial fibrillation in a
patient suffering from atrial fibrillation, the method comprising
the steps of: contacting, in vitro, a portion of a plasma or serum
sample obtained from the patient with a binding agent that
specifically binds Troponin T, said binding agent having a
detectable label, whereby a complex of the binding agent and the
Troponin T is formed; separating the complex from binding agent and
sample not comprising the complex; measuring the amount of complex
separated in said step of separating by detecting the presence of
the detectable label, whereby a concentration of the Troponin T in
the sample is calculated; comparing the concentration of the
Troponin T in the sample to a first Troponin reference
concentration and a second Troponin reference concentration, the
second Troponin reference concentration being greater than the
first Troponin reference concentration; and providing a diagnosis
of intermittent atrial fibrillation in the patient if the
concentration of the Troponin T is greater than the first Troponin
reference concentration and less than the Troponin reference
concentration.
2. The method of claim 1, wherein the binding agent is an
antibody.
3. The method of claim 1, wherein the sample is obtained from the
patient within 6 hours of onset of symptoms of atrial
fibrillation.
4. The method of claim 1, wherein the second Troponin reference
concentration is determined from a Troponin reference concentration
of a sample obtained from at least one individual previously
identified as suffering from atrial fibrillation.
5. The method of claim 4, wherein the first Troponin reference
concentration is determined from a Troponin reference concentration
of a sample obtained from at least one individual previously
identified as not suffering from atrial fibrillation and not
suffering from intermittent atrial fibrillation.
6. A method of diagnosing intermittent atrial fibrillation in a
patient suffering from atrial fibrillation, the method comprising
the steps of: contacting a portion of a serum or plasma sample
obtained from the patient with a capture antibody having specific
binding affinity for a first epitope of Troponin T and with a
detection antibody having specific binding affinity for a second
epitope of Troponin T, thereby forming a complex of the capture
antibody, Troponin T and the detection antibody, the first epitope
being different than the second epitope, the detection antibody
having a detectable label; binding the complex of the capture
antibody, Troponin T and detection antibody with a solid support;
separating the complex of the capture antibody, Troponin T and
detection antibody bound to the solid support from capture
antibody, detection antibody and Troponin T not bound to the solid
support; detecting a signal from the detectable label of the
detection antibody comprising the complex separated from capture
antibody, detection antibody and Troponin T not bound to the solid
support; quantifying the signal detected in said step of detecting,
the signal being proportional to an amount of Troponin T in the
sample from the patient, whereby a concentration of the Troponin T
in the sample is calculated; comparing the concentration of
Troponin T calculated in said step of quantifying to a first
Troponin reference concentration and a second Troponin reference
concentration, the second Troponin reference concentration being
greater than the first Troponin reference concentration; and
providing a diagnosis of intermittent atrial fibrillation in the
patient if the concentration of the Troponin T in the sample
calculated in said step of quantifying is greater than the first
Troponin reference concentration and less than the second Troponin
reference concentration.
7. The method of claim 6, wherein the sample is obtained from the
patient within 6 hours of onset of symptoms of atrial
fibrillation.
8. The method of claim 6, wherein the second Troponin reference
concentration is determined from a Troponin reference concentration
of a sample obtained from at least one individual previously
identified as suffering from atrial fibrillation.
9. The method of claim 6, wherein the first Troponin reference
concentration is determined from a Troponin reference concentration
of a sample obtained from at least one individual previously
identified as not suffering from atrial fibrillation and not
suffering from intermittent atrial fibrillation.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 14/859,616 filed Sep. 21, 2015 (now abandoned), which is a
continuation of U.S. application Ser. No. 14/251,803 filed Apr. 14,
2014 (abandoned), which is a continuation of International
Application No. PCT/EP2012/070553, filed Oct. 17, 2012, which
claims the benefit of European Patent Application No. 11185421.2,
filed Oct. 17, 2011, the disclosures of which are hereby
incorporated by reference in their entirety.
BACKGROUND OF THE DISCLOSURE
[0002] Stroke ranks after ischemic heart disease second as a cause
of lost disability--adjusted life--years in high income countries
and as a cause of death worldwide. If presented early adverse
consequences of stroke can be ameliorated using thrombolysis, in
case of late presentation secondary prevention (to prevent
subsequent stroke) using aspirin and anticoagulation appears the
only appropriate method to avoid disease progression (van der Worp
B and van Gijn J., NEJM 2007: 357: 572-578).
[0003] In order to prevent or treat stroke the identification of
the underlying cause of stroke is of importance. This has been
addressed by the TOAST criteria (Adams H. P. et al Stroke 1993: 24:
35-41). TOAST criteria dissect causes of stroke into
atherothrombotic (atherosclerosis of large vessels), cardioembolic,
lacunar (involving small vessels) and undetermined (Adams H. P. et
al). In order to assess these criteria carotid and transcranial
ultrasound are required as well as echocardiography and an
electrocardiogram (Rodriguez-Yanez et al , Disease Markers 2009:
26: 189-195).
[0004] Cardiac troponins T and I are the preferred biomarkers for
the diagnosis of acute myocardial infarction (Anderson JL, ACC/AHA
2007 guidelines for the management of patients with unstable
angina/non-ST-Elevation myocardial infarction. J Am Coll Cardiol.
2007; 50(7):e1-e157). It has been recognized that elevated troponin
levels may be detected in several non-acute chronic disease states,
including coronary artery disease, heart failure, and chronic
kidney disease (see e.g. Omland et al., N Engl J Med. 2009;
361(26):2538-2547). Troponins T and I are also been shown to be
detectable in individuals from the general population (see e.g.
Wallace et al., Prevalence and determinants of troponin T elevation
in the general population. Circulation. 2006;
113(16):1958-1965).
SUMMARY OF THE DISCLOSURE
[0005] The present disclosure relates to a method for early
differentiating whether a subject suffers from cardioembolic stroke
or from non-cardioembolic ischemic stroke. The method is based on
the determination of the amount of a cardiac Troponin in a sample
from a subject suffering from ischemic stroke obtained not more
than 24 hours after the onset of symptoms of ischemic stroke.
Moreover, the present disclosure relates to a method for diagnosing
atrial fibrillation in a subject. Further envisaged by the present
disclosure are kits and devices adapted to carry out the method of
the present disclosure. The present disclosure also relates to a
system for early differentiating whether a subject suffers from
cardioembolic stroke or from non-cardioembolic ischemic stroke and
for diagnosing atrial fibrillation. Further, the present disclosure
relates to reagents and kits used in performing the methods
disclosed herein.
[0006] In the context of the present disclosure, it has been
surprisingly shown that elevated cardiac Troponin levels in
patients with cardioembolic stroke are detectable already at the
onset of cardioembolic stroke. Thus, the increase of the level of
cardiac Troponins is not caused by the stroke event. Rather, the
studies of the present disclosure suggest that the levels of
cardiac troponins are already increased before the onset of stroke
symptoms. Therefore, the determination of cardiac Troponins allows
for an early differentiation between cardioembolic ischemic stroke
and non-cardioembolic ischemic stroke in the subject. This is
advantageous since the early assessment of the cause of stroke is
crucial in order to sufficiently treat a subject suffering from
stroke, in particular a subject suffering from cardioembolic
stroke. Moreover, strokes due to cardioembolism are in general
severe and prone to early recurrence
DETAILED DESCRIPTION OF THE EMBODIMENTS OF THE DISCLOSURE
[0007] The embodiments disclosed herein are not intended to be
exhaustive or limit the disclosure to the precise form disclosed in
the following detailed description. Rather, the embodiments are
chosen and described so that others skilled in the art may utilize
their teachings.
[0008] Conventional diagnostic techniques usually do not allow for
an early, reliable assessment of the cause of stroke. Accordingly,
a personalized treatment regimen cannot be determined with
sufficient accuracy. As a consequence thereof, many patients will
receive a treatment regimen which is insufficient or which may have
adverse side effects. Therefore, means and methods are required for
reliably differentiating between the causes of stroke.
[0009] Accordingly, the present disclosure method for early
differentiating whether a subject suffers from cardioembolic stroke
or from non-cardioembolic ischemic stroke, comprising [0010] a)
determining the amount of a cardiac Troponin in a sample from a
subject suffering from ischemic stroke, [0011] wherein the sample
has been obtained immediately after the onset of symptoms of
ischemic stroke.
[0012] In an exemplary embodiment the method further comprising the
step of [0013] b) comparing the amount of said cardiac Troponin as
determined in step a to a reference amount, thereby differentiating
whether said subject suffers from cardioembolic stroke or from
non-cardioembolic ischemic stroke.
[0014] Thus, the present disclosure, in particular, relates to a
method for early differentiating whether a subject suffers from
cardioembolic stroke or from non-cardioembolic ischemic stroke,
comprising [0015] a) determining the amount of a cardiac Troponin
in a sample from a subject suffering from ischemic stroke, obtained
immediately after the onset of symptoms of ischemic stroke, and
[0016] b) comparing the amount of said cardiac Troponin as
determined in step a) to a reference amount, whereby it is
differentiated whether said subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke.
[0017] According to exemplary embodiments, it is differentiated,
whether a subject suffers from cardioembolic ischmemic stroke or
from non-cardioembolic ischemic stroke by carrying out the further
step of c) diagnosing whether a subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke, based on
the results of the comparison carried out in step b).
[0018] In an exemplary embodiment of the method of the present
disclosure, step a) further comprises the determination of the
amount of a natriuretic peptide in the sample from the subject
obtained immediately after the onset of ischemic stroke. Thus,
according to exemplary embodiments, the determined amount of the
natriuretic peptide is compared in step b) to a reference amount
for a natriuretic peptide.
[0019] Thus, the present disclosure also relates to a method for
early differentiating whether a subject suffers from cardioembolic
stroke or from non-cardioembolic ischemic stroke, comprising [0020]
a) determining the amount of a cardiac Troponin and of natriuretic
peptide in a sample from a subject suffering from ischemic stroke,
obtained immediately after the onset of symptoms of ischemic
stroke, and [0021] b) comparing the amount of said cardiac Troponin
as determined in step a) to a reference amount for the cardiac
Troponin, and the amount of said natriuretic peptide to a reference
amount for the natriuretic peptide, whereby it is differentiated
whether said subject suffers from cardioembolic stroke or from
non-cardioembolic ischemic stroke.
[0022] The method of the present disclosure, may include, is an ex
vivo method. Moreover, it may comprise steps in addition to those
explicitly mentioned above. For example, further steps may relate
to sample pre-treatments or evaluation of the results obtained by
the method. The method may be carried out manually or assisted by
automation. Preferably, step (a) and/or (b) may in total or in part
be assisted by automation, e.g., by a suitable robotic and sensory
equipment for the determination in step (a) or a
computer-implemented comparison and/or differentiation based on
said comparison in step (b).
[0023] Accordingly, the present disclosure also preferably relates
to a system for early differentiating whether a subject suffers
from cardioembolic ischemic stroke or from non-cardioembolic
ischemic stroke, comprising [0024] a) an analyzer unit configured
to contact, in vitro, a portion of a sample from a subject who
suffers from ischemic stroke with a ligand comprising specific
binding affinity for a cardiac Troponin, [0025] b) an analyzer unit
configured to detect a signal from the portion of the sample from
the subject contacted with the ligand, [0026] c) a computing device
having a processor and in operable communication with said analysis
units, and [0027] d) a non-transient machine readable media
including a plurality of instruction executable by a the processor,
the instructions, when executed calculate an amount of the cardiac
Troponin, and compare the amount of the marker with a reference
amount, thereby differentiating whether a subject suffers from
cardioembolic ischemic stroke or from non-cardioembolic ischemic
stroke.
[0028] The term "differentiating" as used herein means to
distinguish between cardioembolic stroke and non-cardioembolic
stroke in a patient suffering from ischemic stroke. The term as
used herein, preferably, includes differentially diagnosing
cardioembolic ischemic stroke and non-cardioembolic ischemic stroke
in a subject. As will be understood by those skilled in the art,
such an assessment is usually not intended to be correct for 100%
of the subjects to be differentially diagnosed. The term, however,
requires that a statistically significant portion of subjects can
be correctly diagnosed. Whether a diagnosis/differentiation is
correct can be confirmed by methods well known in the art.
Moreover, whether a portion is statistically significant can be
determined without further ado by the person skilled in the art
using various well known statistic evaluation tools, e.g.,
determination of confidence intervals, p-value determination,
Student's t-test, Mann-Whitney test etc.. Details are found in
Dowdy and Wearden, Statistics for Research, John Wiley & Sons,
New York 1983. Preferred confidence intervals are at least 90%, at
least 95%, at least 97%, at least 98% or at least 99%. The p-values
are, preferably, 0.1, 0.05, 0.01, 0.005, or 0.0001.
[0029] The term "subject" as used herein relates to animals,
preferably mammals, and, more preferably, humans. Preferably, the
subject does or not suffer from acute infections. Moreover, it is
further envisaged that the subject does not suffer from acute
coronary syndrome and/or from chronic renal failure. In particular,
the subject in the context with the aforementioned method shall
have normal kidney function. Furthermore, the subject is,
preferably, a subject presenting to an emergency unit.
[0030] The definition of the subject given herein, preferably,
applies to the subject to be tested in accordance with the method
of the present disclosure as well as to the subject/subjects from
which the reference amount is derived.
[0031] The subject to be tested in accordance with the method of
the present disclosure shall suffer from ischemic stroke. The term
"ischemic stroke" (herein also referred to as "stroke") is well
known by the skilled person (see e.g. Adams et al., Guidelines for
the Early Management of Adults With Ischemic Stroke, A Guideline
From the American Heart Association/ American Stroke Association
Stroke Council, Clinical Cardiology Council, Cardiovascular
Radiology and Intervention Council, and the Atherosclerotic
Peripheral Vascular Disease and Quality of Care Outcomes in
Research Interdisciplinary Working Groups in Stroke. 2007; 38:1655;
or Stroke Genetics, edited by Hugh S. Markus, Chapter 1 "An
introduction to stroke, Oxford University Press, Incorporated,
Publish Date 06/03, both of which are herewith incorporated by
reference with respect to its entire disclosure content). As used
herein, the term, preferably, refers to cerebral ischemic stroke.
Ischemic stroke is caused by reduced blood flow to the brain or
parts thereof which leads to a reduced delivery (undersupply) of
oxygen to brain cells. Ischemic stroke may be characterized by
tissue anemia caused by obstruction of the inflow of arterial
blood. It may lead to irreversible tissue damage due to brain cell
death.
[0032] There are various classification systems for ischemic
stroke. The Oxford Community Stroke Project classification (OCSP,
also known as the Bamford or Oxford classification) relies
primarily on the initial symptoms; based on the extent of the
symptoms, the stroke episode is classified as total anterior
circulation infarct (TACI), partial anterior circulation infarct
(PACI), lacunar infarct (LACI) or posterior circulation infarct
(POCI). These four entities predict the extent of the stroke, the
area of the brain affected, the underlying cause, and the
prognosis.
[0033] Preferably, the so called TOAST criteria are applied herein.
For the TOAST criteria, see e.g. Donnan G A, Fisher M, Macleod M,
Davis S M (May 2008). "Stroke". Lancet 371 (9624): 1612-23 or
"Classification of subtype of acute ischemic stroke. Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172
in Acute Stroke Treatment". Stroke 24 (1): 35-41., both of which
are herein incorporated by reference with respect to the entire
disclosure content. The TOAST (Trial of Org 10172 in Acute Stroke
Treatment) classification is based on clinical symptoms as well as
results of further investigations; on this basis, a stroke is
classified as being due to (1) embolism of cardiac origin
(cardioembolic stroke) (2) thrombosis or embolism due to
atherosclerosis of a large artery (large artery stenosis,
atherothrombotic stroke), (3) occlusion of a small blood vessel
(lacunar stroke) or (4) undetermined cause (two possible causes: no
cause identified, or incomplete investigation). Thus, preferred
non-cardioembolic ischemic strokes are atherothrombotic stroke (see
2) and lacunar stroke (see 3).
[0034] Whether a subject suffers from stroke, in particular from
ischemic stroke can be determined by well-known methods. Moreover,
symptoms of stroke are well known in the art and e.g. described in
Adams et al. (loc. cit.). E.g., stroke symptoms include sudden
numbness or weakness of face, arm or leg, especially on one side of
the body, sudden confusion, trouble speaking or understanding,
sudden trouble seeing in one or both eyes, and sudden trouble
walking, dizziness, loss of balance or coordination.
[0035] The term "sample" refers to a sample of a body fluid, to a
sample of separated cells or to a sample from a tissue or an organ.
Samples of body fluids can be obtained by well known techniques and
include, preferably, samples of blood, plasma, serum, or urine,
more preferably, samples of blood, plasma or serum. Tissue or organ
samples may be obtained from any tissue or organ by, e.g., biopsy.
Separated cells may be obtained from the body fluids or the tissues
or organs by separating techniques such as centrifugation or cell
sorting. Preferably, cell-, tissue- or organ samples are obtained
from those cells, tissues or organs which express or produce the
peptides referred to herein.
[0036] The sample to be tested in the context of the method of the
present disclosure shall have been obtained immediately after the
onset of symptoms of stroke (as well as the reference sample).
Preferably, a sample is deemed to have been obtained immediately
after the onset of symptoms of stroke if it has been obtained from
said subject not more than 24 hours, in particular not more than 12
hours after the onset of symptoms of stroke. More preferably, a
sample is deemed to have been obtained immediately after the onset
of symptoms of stroke if it has been obtained from said subject not
more than 6 hours, and even more preferably not more than 3 hours
after the onset of symptoms of ischemic stroke. Further envisaged
is that the sample has been obtained not more than one or two hours
after the onset of stroke symptoms.
[0037] The term "cardiac Troponin" refers to all Troponin isoforms
expressed in cells of the heart and, preferably, the subendocardial
cells. These isoforms are well characterized in the art as
described, e.g., in Anderson 1995, Circulation Research, vol. 76,
no. 4: 681-686 and Ferrieres 1998, Clinical Chemistry, 44: 487-493.
Preferably, cardiac Troponin refers to Troponin T and/or Troponin
I, and, most preferably, to Troponin T. It is to be understood that
isoforms of Troponins may be determined in the method of the
present disclosure together, i.e. simultaneously or sequentially,
or individually, i.e. without determining the other isoform at all.
Amino acid sequences for human Troponin T and human Troponin I are
disclosed in Anderson, loc cit and Ferrieres 1998, Clinical
Chemistry, 44: 487-493.
[0038] The term "cardiac Troponin" encompasses also variants of the
aforementioned specific Troponins, i.e., preferably, of Troponin I,
and more preferably, of Troponin T. Such variants have at least the
same essential biological and immunological properties as the
specific cardiac Troponins. In particular, they share the same
essential biological and immunological properties if they are
detectable by the same specific assays referred to in this
specification, e.g., by ELISA Assays using polyclonal or monoclonal
antibodies specifically recognizing the said cardiac Troponins.
Moreover, it is to be understood that a variant as referred to in
accordance with the present disclosure shall have an amino acid
sequence which differs due to at least one amino acid substitution,
deletion and/or addition wherein the amino acid sequence of the
variant is still, preferably, at least about 50%, at least about
60%, at least about 70%, at least about 80%, at least about 85%, at
least about 90%, at least about 92%, at least about 95%, at least
about 97%, at least about 98%, or at least about 99% identical with
the amino sequence of the specific Troponin. Preferably, the degree
of identity is to be determined by comparing two optimally aligned
sequences over a comparison window, where the fragment of amino
acid sequence in the comparison window may comprise additions or
deletions (e.g., gaps or overhangs) as compared to the reference
sequence (which does not comprise additions or deletions) for
optimal alignment. The percentage is calculated by determining the
number of positions at which the identical amino acid residue
occurs in both sequences to yield the number of matched positions,
dividing the number of matched positions by the total number of
positions in the window of comparison and multiplying the result by
100 to yield the percentage of sequence identity. Optimal alignment
of sequences for comparison may be conducted by the local homology
algorithm of Smith and Waterman Add. APL. Math. 2:482 (1981), by
the homology alignment algorithm of Needleman and Wunsch J. Mol.
Biol. 48:443 (1970), by the search for similarity method of Pearson
and Lipman Proc. Natl. Acad. Sci. (USA) 85: 2444 (1988), by
computerized implementations of these algorithms (GAP, BESTFIT,
BLAST, PASTA, and TFASTA in the Wisconsin Genetics Software
Package, Genetics Computer Group (GCG), 575 Science Dr., Madison,
Wis.), or by visual inspection. Given that two sequences have been
identified for comparison, GAP and BESTFIT are preferably employed
to determine their optimal alignment and, thus, the degree of
identity. Preferably, the default values of 5.00 for gap weight and
0.30 for gap weight length are used. Variants may be allelic
variants or any other species specific homologs, paralogs, or
orthologs. Moreover, the variants referred to herein include
fragments of the specific cardiac Troponins or the aforementioned
types of variants as long as these fragments have the essential
immunological and biological properties as referred to above.
Preferably, the cardiac troponin variants have immunological
properties (i.e. epitope composition) comparable to those of human
troponin T or troponin I. Thus, the variants shall be recognizable
by the aforementioned means or ligands used for determination of
the concentration of the cardiac troponins. Thus, the variants
shall be recognizable by the aforementioned means or ligands used
for determination of the concentration of the cardiac troponins.
Such fragments may be, e.g., degradation products of the Troponins.
Further included are variants which differ due to posttranslational
modifications such as phosphorylation or myristylation. Preferably
the biological property of troponin I and its variant is the
ability to inhibit actomyosin ATPase or to inhibit angiogenesis in
vivo and in vitro, which may e.g. be detected based on the assay
described by Moses et al. 1999 PNAS USA 96 (6): 2645-2650).
Preferably the biological property of troponin T and its variant is
the ability to form a complex with troponin C and I, to bind
calcium ions or to bind to tropomyosin, preferably if present as a
complex of troponin C, I and T or a complex formed by troponin C,
troponin I and a variant of troponin T. It is known that low
concentrations of circulating cardiac troponin may be detected in
subjects at various conditions, but further studies are required to
understand their respective role and rate (Masson et al., Curr
Heart Fail Rep (2010) 7:15-21).
[0039] The term "natriuretic peptide" comprises Atrial Natriuretic
Peptide (ANP)-type and Brain Natriuretic Peptide (BNP)-type
peptides and variants thereof having the same predictive potential.
Natriuretic peptides according to the present disclosure comprise
ANP-type and BNP-type peptides and variants thereof (see e.g.
Bonow, 1996, Circulation 93: 1946-1950). ANP-type peptides comprise
pre-proANP, proANP, NT-proANP, and ANP. BNP-type peptides comprise
pre-proBNP, proBNP, NT-proBNP, and BNP. The pre-pro peptide (134
amino acids in the case of pre-proBNP) comprises a short signal
peptide, which is enzymatically cleaved off to release the pro
peptide (108 amino acids in the case of proBNP). The pro peptide is
further cleaved into an N-terminal pro peptide (NT-pro peptide, 76
amino acids in case of NT-proBNP) and the active hormone (32 amino
acids in the case of BNP, 28 amino acids in the case of ANP).
Preferably, natriuretic peptides according to the present
disclosure are NT-proANP, ANP, and, more preferably, NT-proBNP,
BNP, and variants thereof. ANP and BNP are the active hormones and
have a shorter half-life than their respective inactive
counterparts, NT-proANP and NT-proBNP. BNP is metabolized in the
blood, whereas NT-proBNP circulates in the blood as an intact
molecule and as such is eliminated renally. The in-vivo half-life
of NT-proBNP is 120 min longer than that of BNP, which is 20 min
(Smith 2000, J Endocrinol. 167: 239-46.). Preanalytics are more
robust with NT-proBNP allowing easy transportation of the sample to
a central laboratory (Mueller 2004, Clin Chem Lab Med 42: 942-4.).
Blood samples can be stored at room temperature for several days or
may be mailed or shipped without recovery loss. In contrast,
storage of BNP for 48 hours at room temperature or at 4.degree.
Celsius leads to a concentration loss of at least 20% (Mueller
loc.cit.; Wu 2004, Clin Chem 50: 867-73.). Therefore, depending on
the time-course or properties of interest, either measurement of
the active or the inactive forms of the natriuretic peptide can be
advantageous. The most preferred natriuretic peptides according to
the present disclosure are NT-proBNP or variants thereof. As
briefly discussed above, the human NT-proBNP, as referred to in
accordance with the present disclosure, is a polypeptide
comprising, preferably, 76 amino acids in length corresponding to
the N-terminal portion of the human NT-proBNP molecule. The
structure of the human BNP and NT-proBNP has been described already
in detail in the prior art, e.g., WO 02/089657, WO 02/083913 or
Bonow loc. cit. Preferably, human NT-proBNP as used herein is human
NT-proBNP as disclosed in EP 0 648 228 B1. These prior art
documents are herewith incorporated by reference with respect to
the specific sequences of NT-proBNP and variants thereof disclosed
therein. The NT-proBNP referred to in accordance with the present
disclosure further encompasses allelic and other variants of said
specific sequence for human NT-proBNP discussed above.
Specifically, envisaged are variant polypeptides which are on the
amino acid level preferably, at least 50%, 60%, 70%, 80%, 85%, 90%,
92%, 95%, 97%, 98%, or 99% identical to human NT-proBNP, preferably
over the entire length of human NT-proBNP. The degree of identity
between two amino acid sequences can be determined by algorithms
well known in the art. Preferably, the degree of identity is to be
determined by comparing two optimally aligned sequences over a
comparison window, where the fragment of amino acid sequence in the
comparison window may comprise additions or deletions (e.g., gaps
or overhangs) as compared to the reference sequence (which does not
comprise additions or deletions) for optimal alignment. The
percentage is calculated by determining the number of positions at
which the identical amino acid residue occurs in both sequences to
yield the number of matched positions, dividing the number of
matched positions by the total number of positions in the window of
comparison and multiplying the result by 100 to yield the
percentage of sequence identity. Optimal alignment of sequences for
comparison may be conducted by the local homology algorithm of
Smith and Waterman Add. APL. Math. 2:482 (1981), by the homology
alignment algorithm of Needleman and Wunsch J. Mol. Biol. 48:443
(1970), by the search for similarity method of Pearson and Lipman
Proc. Natl. Acad. Sci. (USA) 85: 2444 (1988), by computerized
implementations of these algorithms (GAP, BESTFIT, BLAST, PASTA,
and TFASTA in the Wisconsin Genetics Software Package, Genetics
Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by visual
inspection. Given that two sequences have been identified for
comparison, GAP and BESTFIT are preferably employed to determine
their optimal alignment and, thus, the degree of identity.
Preferably, the default values of 5.00 for gap weight and 0.30 for
gap weight length are used. Variants referred to above may be
allelic variants or any other species specific homologs, paralogs,
or orthologs. Substantially similar and also envisaged are
proteolytic degradation products which are still recognized by the
diagnostic means or by ligands directed against the respective
full-length peptide. Also encompassed are variant polypeptides
having amino acid deletions, substitutions, and/or additions
compared to the amino acid sequence of human NT-proBNP as long as
the said polypeptides have NT-proBNP properties. NT-proBNP
properties as referred to herein are immunological and/or
biological properties. Preferably, the NT- proBNP variants have
immunological properties (i.e. epitope composition) comparable to
those of human NT-proBNP. Thus, the variants shall be recognizable
by the aforementioned means or ligands used for determination of
the amount of the natriuretic peptides. Biological and/or
immunological NT-proBNP properties can be detected by the assay
described in Karl et al. (Karl 1999, Scand J Clin Lab Invest
230:177-181), Yeo et al. (Yeo 2003, Clinica Chimica Acta
338:107-115). Variants also include posttranslationally modified
peptides such as glycosylated peptides. Further, a variant in
accordance with the present disclosure is also a peptide or
polypeptide which has been modified after collection of the sample,
for example by covalent or non-covalent attachment of a label,
particularly a radioactive or fluorescent label, to the
peptide.
[0040] Determining the amount of a peptide or polypeptide referred
to in this specification relates to measuring the amount or
concentration, preferably, semi-quantitatively or quantitatively.
Measuring can be done directly or indirectly. Direct measuring
relates to measuring the amount or concentration of the peptide or
polypeptide based on a signal which is obtained from the peptide or
polypeptide itself and the intensity of which directly correlates
with the number of molecules of the peptide present in the sample.
Such a signal--sometimes referred to herein as intensity
signal--may be obtained, e.g., by measuring an intensity value of a
specific physical or chemical property of the peptide or
polypeptide. Indirect measuring includes measuring of a signal
obtained from a secondary component (i.e. a component not being the
peptide or polypeptide itself) or a biological read out system,
e.g., measurable cellular responses, ligands, labels, or enzymatic
reaction products.
[0041] In accordance with the present disclosure, determining the
amount of a peptide or polypeptide can be achieved by all known
means for determining the amount of a peptide in a sample. Said
means comprise immunoassay and methods which may utilize labeled
molecules in various sandwich, competition, or other assay formats.
Such assays are, preferably, based on detection agents such as
antibodies which specifically recognize the peptide or polypeptide
to be determined. The detection agents shall be either directly or
indirectly capable of generating a signal indicating the presence
or absence of the peptide or polypeptide. Moreover, the signal
strength can, preferably, be correlated directly or indirectly
(e.g. reverse-proportional) to the amount of polypeptide present in
a sample. Further suitable methods comprise measuring a physical or
chemical property specific for the peptide or polypeptide such as
its precise molecular mass or NMR spectrum. Said methods comprise,
preferably, biosensors, optical devices coupled to immunoassays,
biochips, analytical devices such as mass-spectrometers,
NMR-analyzers, or chromatography devices. Further, methods include
micro-plate ELISA-based methods, fully-automated or robotic
immunoassays (available for example on Elecsys.TM. analyzers), CBA
(an enzymatic Cobalt Binding Assay, available for example on
Roche-Hitachi.TM. analyzers), and latex agglutination assays
(available for example on Roche-Hitachi.TM. analyzers).
[0042] Preferably, determining the amount of a peptide or
polypeptide comprises the steps of (a) contacting a cell capable of
eliciting a cellular response the intensity of which is indicative
of the amount of the peptide or polypeptide with the said peptide
or polypeptide for an adequate period of time, (b) measuring the
cellular response. For measuring cellular responses, the sample or
processed sample is, preferably, added to a cell culture and an
internal or external cellular response is measured. The cellular
response may include the measurable expression of a reporter gene
or the secretion of a substance, e.g. a peptide, polypeptide, or a
small molecule. The expression or substance shall generate an
intensity signal which correlates to the amount of the peptide or
polypeptide.
[0043] Also preferably, determining the amount of a peptide or
polypeptide comprises the step of measuring a specific intensity
signal obtainable from the peptide or polypeptide in the sample. As
described above, such a signal may be the signal intensity observed
at an m/z variable specific for the peptide or polypeptide observed
in mass spectra or a NMR spectrum specific for the peptide or
polypeptide.
[0044] Determining the amount of a peptide or polypeptide may,
preferably, comprises the steps of (a) contacting the peptide with
a specific ligand, (b) (optionally) removing non-bound ligand, (c)
measuring the amount of bound ligand.
[0045] According to a preferred embodiment, said steps of
contacting, removing and measuring may be performed by an analyzer
unit of the system disclosed herein. According to some embodiments,
said steps may be performed by a single analyzer unit of said
system or by more than one analyzer unit in operable communication
with each other. For example, according to a specific embodiment,
said system disclosed herein may include a first analyzer unit for
performing said steps of contacting and removing and a second
analyzer unit, operably connected to said first analyzer unit by a
transport unit (for example, a robotic arm), which performs said
step of measuring.
[0046] The bound ligand, in particular the ligand or the
ligand/peptide complex, will generate an intensity signal. Binding
according to the present disclosure includes both covalent and
non-covalent binding. A ligand according to the present disclosure
can be any compound, e.g., a peptide, polypeptide, nucleic acid, or
small molecule, binding to the peptide or polypeptide described
herein. Preferred ligands include antibodies, nucleic acids,
peptides or polypeptides such as receptors or binding partners for
the peptide or polypeptide and fragments thereof comprising the
binding domains for the peptides, and aptamers, e.g. nucleic acid
or peptide aptamers. Methods to prepare such ligands are well-known
in the art. For example, identification and production of suitable
antibodies or aptamers is also offered by commercial suppliers. The
person skilled in the art is familiar with methods to develop
derivatives of such ligands with higher affinity or specificity.
For example, random mutations can be introduced into the nucleic
acids, peptides or polypeptides. These derivatives can then be
tested for binding according to screening procedures known in the
art, e.g. phage display. Antibodies as referred to herein include
both polyclonal and monoclonal antibodies, as well as fragments
thereof, such as Fv, Fab and F(ab)2 fragments that are capable of
binding antigen or hapten. The present disclosure also includes
single chain antibodies and humanized hybrid antibodies wherein
amino acid sequences of a non-human donor antibody exhibiting a
desired antigen-specificity are combined with sequences of a human
acceptor antibody. The donor sequences will usually include at
least the antigen-binding amino acid residues of the donor but may
comprise other structurally and/or functionally relevant amino acid
residues of the donor antibody as well. Such hybrids can be
prepared by several methods well known in the art. Preferably, the
ligand or agent binds specifically to the peptide or polypeptide.
Specific binding according to the present disclosure means that the
ligand or agent should not bind substantially to ("cross-react"
with) another peptide, polypeptide or substance present in the
sample to be analyzed. Preferably, the specifically bound peptide
or polypeptide should be bound with at least 3 times higher, more
preferably at least 10 times higher and even more preferably at
least 50 times higher affinity than any other relevant peptide or
polypeptide. Non-specific binding may be tolerable, if it can still
be distinguished and measured unequivocally, e.g. according to its
size on a Western Blot, or by its relatively higher abundance in
the sample. Binding of the ligand can be measured by any method
known in the art. Preferably, said method is semi-quantitative or
quantitative. Further suitable techniques for the determination of
a polypeptide or peptide are described in the following.
[0047] First, binding of a ligand may be measured directly, e.g. by
NMR or surface plasmon resonance. Measurement of the binding of a
ligand, according to preferred embodiments, is performed by an
analyzer unit of a system disclosed herein. Thereafter, an amount
of the measured binding may be calculated by a computing device of
a system disclosed herein. Second, if the ligand also serves as a
substrate of an enzymatic activity of the peptide or polypeptide of
interest, an enzymatic reaction product may be measured (e.g. the
amount of a protease can be measured by measuring the amount of
cleaved substrate, e.g. on a Western Blot). Alternatively, the
ligand may exhibit enzymatic properties itself and the
"ligand/peptide or polypeptide" complex or the ligand which was
bound by the peptide or polypeptide, respectively, may be contacted
with a suitable substrate allowing detection by the generation of
an intensity signal. For measurement of enzymatic reaction
products, preferably the amount of substrate is saturating. The
substrate may also be labeled with a detectable lable prior to the
reaction. Preferably, the sample is contacted with the substrate
for an adequate period of time. An adequate period of time refers
to the time necessary for an detectable, preferably measurable,
amount of product to be produced. Instead of measuring the amount
of product, the time necessary for appearance of a given (e.g.
detectable) amount of product can be measured. Third, the ligand
may be coupled covalently or non-covalently to a label allowing
detection and measurement of the ligand. Labeling may be done by
direct or indirect methods. Direct labeling involves coupling of
the label directly (covalently or non-covalently) to the ligand.
Indirect labeling involves binding (covalently or non-covalently)
of a secondary ligand to the first ligand. The secondary ligand
should specifically bind to the first ligand. Said secondary ligand
may be coupled with a suitable label and/or be the target
(receptor) of tertiary ligand binding to the secondary ligand. The
use of secondary, tertiary or even higher order ligands is often
used to increase the signal. Suitable secondary and higher order
ligands may include antibodies, secondary antibodies, and the
well-known streptavidin-biotin system (Vector Laboratories, Inc.).
The ligand or substrate may also be "tagged" with one or more tags
as known in the art. Such tags may then be targets for higher order
ligands. Suitable tags include biotin, digoxygenin, His-Tag,
Glutathion-S-Transferase, FLAG, GFP, myc-tag, influenza A virus
haemagglutinin (HA), maltose binding protein, and the like. In the
case of a peptide or polypeptide, the tag is preferably at the
N-terminus and/or C-terminus. Suitable labels are any labels
detectable by an appropriate detection method. Typical labels
include gold particles, latex beads, acridan ester, luminol,
ruthenium, enzymatically active labels, radioactive labels,
magnetic labels ("e.g. magnetic beads", including paramagnetic and
superparamagnetic labels), and fluorescent labels. Enzymatically
active labels include e.g. horseradish peroxidase, alkaline
phosphatase, beta-Galactosidase, Luciferase, and derivatives
thereof. Suitable substrates for detection include
di-amino-benzidine (DAB), 3,3'-5,5'-tetramethylbenzidine, NBT-BCIP
(4-nitro blue tetrazolium chloride and
5-bromo-4-chloro-3-indolyl-phosphate, available as ready-made stock
solution from Roche Diagnostics), CDP-Star.TM. (Amersham
Biosciences), ECF.TM. (Amersham Biosciences). A suitable
enzyme-substrate combination may result in a colored reaction
product, fluorescence or chemoluminescence, which can be measured
according to methods known in the art (e.g. using a light-sensitive
film or a suitable camera system). As for measuring the enyzmatic
reaction, the criteria given above apply analogously. Typical
fluorescent labels include fluorescent proteins (such as GFP and
its derivatives), Cy3, Cy5, Texas Red, Fluorescein, and the Alexa
dyes (e.g. Alexa 568). Further fluorescent labels are available
e.g. from Molecular Probes (Oregon). Also the use of quantum dots
as fluorescent labels is contemplated. Typical radioactive labels
include 35S, 125I, 32P, 33P and the like. A radioactive label can
be detected by any method known and appropriate, e.g. a
light-sensitive film or a phosphor imager. Suitable measurement
methods according the present disclosure also include precipitation
(particularly immunoprecipitation), electrochemiluminescence
(electro-generated chemiluminescence), RIA (radioimmunoassay),
ELISA (enzyme-linked immunosorbent assay), sandwich enzyme immune
tests, electrochemiluminescence sandwich immunoassays (ECLIA),
dissociation-enhanced lanthanide fluoro immuno assay (DELFIA),
scintillation proximity assay (SPA), turbidimetry, nephelometry,
latex-enhanced turbidimetry or nephelometry, or solid phase immune
tests. Further methods known in the art (such as gel
electrophoresis, 2D gel electrophoresis, SDS polyacrylamid gel
electrophoresis (SDS-PAGE), Western Blotting, and mass
spectrometry), can be used alone or in combination with labeling or
other dectection methods as described above.
[0048] The amount of a peptide or polypeptide may be, also
preferably, determined as follows: (a) contacting a solid support
comprising a ligand for the peptide or polypeptide as specified
above with a sample comprising the peptide or polypeptide and (b)
measuring the amount peptide or polypeptide which is bound to the
support. The ligand, preferably chosen from the group consisting of
nucleic acids, peptides, polypeptides, antibodies and aptamers, is
preferably present on a solid support in immobilized form.
Materials for manufacturing solid supports are well known in the
art and include, inter alia, commercially available column
materials, polystyrene beads, latex beads, magnetic beads, colloid
metal particles, glass and/or silicon chips and surfaces,
nitrocellulose strips, membranes, sheets, duracytes, wells and
walls of reaction trays, plastic tubes etc. The ligand or agent may
be bound to many different carriers. Examples of well-known
carriers include glass, polystyrene, polyvinyl chloride,
polypropylene, polyethylene, polycarbonate, dextran, nylon,
amyloses, natural and modified celluloses, polyacrylamides,
agaroses, and magnetite. The nature of the carrier can be either
soluble or insoluble for the purposes of the disclosure. Suitable
methods for fixing/immobilizing said ligand are well known and
include, but are not limited to ionic, hydrophobic, covalent
interactions and the like. It is also contemplated to use
"suspension arrays" as arrays according to the present disclosure
(Nolan 2002, Trends Biotechnol. 20(1):9-12). In such suspension
arrays, the carrier, e.g. a microbead or microsphere, is present in
suspension. The array consists of different microbeads or
microspheres, possibly labeled, carrying different ligands. Methods
of producing such arrays, for example based on solid-phase
chemistry and photo-labile protective groups, are generally known
(U.S. Pat. No. 5,744,305).
[0049] The term "amount" as used herein encompasses the absolute
amount of a polypeptide or peptide, the relative amount or
concentration of the said polypeptide or peptide as well as any
value or parameter which correlates thereto or can be derived
therefrom. Such values or parameters comprise intensity signal
values from all specific physical or chemical properties obtained
from the said peptides by direct measurements, e.g., intensity
values in mass spectra or NMR spectra. Moreover, encompassed are
all values or parameters which are obtained by indirect
measurements specified elsewhere in this description, e.g.,
response amounts determined from biological read out systems in
response to the peptides or intensity signals obtained from
specifically bound ligands. It is to be understood that values
correlating to the aforementioned amounts or parameters can also be
obtained by all standard mathematical operations. According to
preferred embodiments of the subject disclosure, the determination
of an "amount" is performed by the disclosed system, whereby a
computing device determines the "amount" based on contacting and
measuring steps performed by one or more analyzer units of said
system.
[0050] The term "comparing" as used herein encompasses comparing
the amount of the peptide or polypeptide comprised by the sample to
be analyzed with an amount of a suitable reference source specified
elsewhere in this description. It is to be understood that
comparing as used herein refers to a comparison of corresponding
parameters or values, e.g., an absolute amount is compared to an
absolute reference amount while a concentration is compared to a
reference concentration or an intensity signal obtained from a test
sample is compared to the same type of intensity signal of a
reference sample. The comparison referred to in step (b) of the
method of the present disclosure may be carried out manually or
computer assisted. Thus, the comparison referred to in step (b) of
the method of the present disclosure may be carried out by a
computing device (e.g., of a system disclosed herein). The value of
the amount and the reference can be, e.g., compared to each other
and the said comparison can be automatically carried out by a
computer program executing an algorithm for the comparison. The
computer program carrying out the said evaluation will provide the
desired assessment in a suitable output format. For a computer
assisted comparison, the value of the determined amount may be
compared to values corresponding to suitable references which are
stored in a database by a computer program. The computer program
may further evaluate the result of the comparison, i.e.
automatically provide the desired assessment in a suitable output
format.
[0051] For a computer assisted comparison, the value of the
determined amount may be compared to values corresponding to
suitable references which are stored in a database by a computer
program. The computer program may further evaluate the result of
the comparison, i.e. automatically provides the desired assessment
in a suitable output format. The said result may, preferably, serve
as an aid in differentiating between cardioembolic and
non-cardioembolic ischemic stroke.
[0052] For example, a result of a comparison may be given as raw
data (absolute or relative amounts), and in some cases as an
indicator in the form of a word, phrase, symbol, or numerical value
which may be indicative of a particular diagnosis.
[0053] The term "reference amount" as used herein refers to an
amount which allows for allocation of a subject into either the
group of subjects suffering from cardioembolic ischemic stroke or
into a group of subject suffering from non-cardioembolic ischemic
stroke. Such a reference amount can be a threshold amount which
separates these groups from each other. Accordingly, the reference
amount for a the biomarker Troponin shall be an amount which allows
for allocation of a subject into a group of subjects suffering from
cardioembolic ischemic stroke or into a group of subjects suffering
from non-cardioembolic ischemic stroke. A suitable threshold amount
separating the two groups can be calculated without further ado by
the statistical tests referred to herein elsewhere based on amounts
of a cardiac Troponin from either a subject or group of subjects
suffering from cardioembolic ischemic stroke or a subject or group
of subjects suffering from non-cardioembolic ischemic stroke.
Preferred referenced amounts which can be derived from the
aforementioned subjects or group of subjects are indicated
elsewhere herein.
[0054] Reference amounts can, in principle, be calculated for a
cohort of subjects as specified above based on the average or mean
values for a given biomarker by applying standard statistically
methods. In particular, accuracy of a test such as a method aiming
to diagnose an event, or not, is best described by its
receiver-operating characteristics (ROC) (see especially Zweig
1993, Clin. Chem. 39:561-577). The ROC graph is a plot of all of
the sensitivity/specificity pairs resulting from continuously
varying the decision threshold over the entire range of data
observed. The clinical performance of a diagnostic method depends
on its accuracy, i.e. its ability to correctly allocate subjects to
a certain prognosis or diagnosis. The ROC plot indicates the
overlap between the two distributions by plotting the sensitivity
versus 1-specificity for the complete range of thresholds suitable
for making a distinction. On the y-axis is sensitivity, or the
true-positive fraction, which is defined as the ratio of number of
true-positive test results to the product of number of
true-positive and number of false-negative test results. This has
also been referred to as positivity in the presence of a disease or
condition. It is calculated solely from the affected subgroup. On
the x-axis is the false-positive fraction, or 1-specificity, which
is defined as the ratio of number of false-positive results to the
product of number of true-negative and number of false-positive
results. It is an index of specificity and is calculated entirely
from the unaffected subgroup. Because the true- and false-positive
fractions are calculated entirely separately, by using the test
results from two different subgroups, the ROC plot is independent
of the prevalence of the event in the cohort. Each point on the ROC
plot represents a sensitivity/-specificity pair corresponding to a
particular decision threshold. A test with perfect discrimination
(no overlap in the two distributions of results) has an ROC plot
that passes through the upper left corner, where the true-positive
fraction is 1.0, or 100% (perfect sensitivity), and the
false-positive fraction is 0 (perfect specificity). The theoretical
plot for a test with no discrimination (identical distributions of
results for the two groups) is a 45.degree. diagonal line from the
lower left corner to the upper right corner. Most plots fall in
between these two extremes. If the ROC plot falls completely below
the 45.degree. diagonal, this is easily remedied by reversing the
criterion for "positivity" from "greater than" to "less than" or
vice versa. Qualitatively, the closer the plot is to the upper left
corner, the higher the overall accuracy of the test. Dependent on a
desired confidence interval, a threshold can be derived from the
ROC curve allowing for the diagnosis or prediction for a given
event with a proper balance of sensitivity and specificity,
respectively. Accordingly, the reference to be used for the
aforementioned method of the present disclosure can be, preferably,
a threshold or cut off amount and can be generated, preferably, by
establishing a ROC for said cohort as described above and deriving
a threshold amount therefrom. Dependent on a desired sensitivity
and specificity for a diagnostic method, the ROC plot allows
deriving suitable thresholds.
[0055] The diagnosis/differentiation referred to herein may be
provided by the computing device of a system disclosed herein based
on said comparison of the calculated "amount" to a reference or a
threshold. For example, a computing device of a system may provide
an indicator, in the form of a word, symbol, or numerical value
which is indicative of one cardioembolic stroke or
non-cardioembolic stroke.
[0056] Preferably, the reference amount(s) is (are) derived from a
subject or a group of subjects known to suffer from cardioembolic
ischemic stroke. In this case, an essentially identical amount or
an increased amount of a cardiac Troponin in the test sample as
compared to reference amount is, preferably, indicative for
cardioembolic ischemic stroke. If also a natriuretic peptide is
determined, an essentially identical amount or an increased amount
of a cardiac Troponin and of the natriuretic peptide in the test
sample as compared to reference amount for the cardiac Troponin and
the reference amount for the natriuretic peptide is, preferably,
indicative for cardioembolic ischemic stroke.
[0057] Also preferably, the reference amount for a cardiac Troponin
(and, optionally, of the natriuretic peptide) may be derived from a
subject or a group of subjects known to suffer from
non-cardioembolic ischemic stroke. In this case, an essentially
identical amount or a decreased amount of the cardiac Troponin
(and, optionally, of the natriuretic peptide) in the test sample as
compared to reference amount is indicative for non-cardioembolic
ischemic stroke. If also a natriuretic peptide is determined, an
essentially identical amount or a decreased amount of the cardiac
Troponin of the natriuretic peptide in the test sample as compared
to the reference amount for the cardiac Troponin and the reference
amount for the natriuretic peptide is indicative for
non-cardioembolic ischemic stroke.
[0058] The reference amount applicable for an individual subject
may vary depending on various physiological parameters such as age,
gender, or subpopulation, as well as on the means used for the
determination of the polypeptide or peptide referred to herein. A
suitable reference amount may be determined from a reference sample
to be analyzed together, i.e. simultaneously or subsequently, with
the test sample.
[0059] Further, the reference amount may define a threshold amount,
in particular a calculated reference amount, for the cardiac
Troponin (and, optionally for the natriuretic peptide), whereby an
amount of Troponin (and, optionally of the natriuretic peptide) in
the sample of the test subject larger than the respective threshold
shall be indicative for cardioembolic ischemic stroke, while an
amount of Troponin (and, optionally, of the natriuretic peptide) in
the sample of the test subject lower than the respective threshold
shall be indicative for non-cardioembolic stroke.
[0060] Preferred reference amounts are indicated herein below.
[0061] A preferred reference amount indicating cardioembolic
ischemic stroke is an amount of a cardiac troponin, in particular
of Troponin T of about 8 pg/ml to about 40 pg/ml and, more
preferably, 10 to 30 pg/ml, about 11.6 to about 20 pg/ml, even more
preferably of about 15 to 20 pg/ml. Even more preferably, the
reference is an amount of about 8, 10, or 11.6 pg/ml. A test amount
being essentially identical or increased shall be indicative for
cardioembolic ischemic stroke while a decreased amount in the test
sample as compared to the reference amount shall be indicative for
non-cardioembolic ischemic stroke. Preferably, the aforementioned
reference amounts are derived from a subject or a group of subjects
known to suffer from cardioembolic ischemic stroke.
[0062] The present disclosure is, particularly, useful for ruling
out cardioembolic stroke. In particular, a test amount of a cardiac
Troponin, preferably, of Troponin T, being lower than 5 pg/ml, in
particular lower than 3 or lower than 2 pg/mg indicates that the
subject does not suffer from cardioembolic stroke (and, thus,
preferably, suffers from non-cardioembolic stroke).
[0063] A preferred reference amount indicating cardioembolic
ischemic stroke is an amount of a natriuretic peptide, in
particular, of NT-proBNP of about 500 pg/ml to about 1500 pg/ml
and, more preferably, 700 to 1300 pg/ml, even more preferably of
about 800 to 1000 pg/ml. Even more preferably, the reference is an
amount of about 700, 800, or most preferably 900 pg/ml. A test
amount being essentially identical or increased shall be indicative
for cardioembolic ischemic stroke while a decreased amount in the
test sample as compared to the reference amount shall be indicative
for non-cardioembolic ischemic stroke. Preferably, the
aforementioned reference amounts are derived from a subject or a
group of subjects known to suffer from cardioembolic ischemic
stroke (in addition to the amount of the cardiac Troponin).
[0064] As set forth above, the present disclosure is, particularly,
useful for ruling out cardioembolic stroke. In particular, a test
amount of a natriuretic peptide, in particular of NT-proBNP being
lower than 250 pg/ml, in particular lower than 200 or lower than
150 pg/mg indicates that the subject does not suffer from
cardioembolic stroke (and, thus, preferably, suffers from
non-cardioembolic stroke).
[0065] The term "about" in the context of the present disclosure
means +/-20%, +/-10%, +/-5%, +/-2% or +/-1% from the said values.
This also takes into account usual deviations caused by measurement
techniques, statistics and the like.
[0066] In some embodiments of the method of the present disclosure,
said method further comprises recommending a therapy for said
subject, in particular, if the subject has been diagnosed to suffer
from cardioembolic stroke. A therapy that can be recommended in a
subject who suffers from cardioembolic stroke is lytic therapy
and/or anticoagulation therapy (see e.g. Cairns J. A. et al
Canadian J of Cardiology 2011: 27: 74-90 or Camm A. J. et al Eur
Heart Journal 2010: 31: 2369-429 which are both incorporated herein
by reference).
[0067] In an aspect of the disclosure, a method for differentiating
whether a subject suffers from cardioembolic ischemic stroke or
from non-cardioembolic ischemic stroke, is contemplated, said
method comprising: [0068] a) determining the amount of a cardiac
Troponin in a sample from a subject suffering from ischemic stroke
by (i) bringing the sample into contact with a detection agent that
specifically binds to said cardiac Troponin for a time sufficient
to allow for the formation of a complex of the said detection agent
and the cardiac Troponin from the sample, (ii) measuring the amount
of the formed complex, wherein the said amount of the formed
complex is proportional to the amount of the at cardiac Troponin
present in the sample, and (iii) transforming the amount of the
formed complex into an amount of the cardiac Troponin reflecting
the amount of the marker present in the sample; [0069] b) comparing
said amount to a reference; and [0070] c) establishing an aid for
differentiating whether a subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke, based on
the result of the comparison made in step b).
[0071] Preferably, also the amount of a natriuretic peptide is
determined.
[0072] In another aspect of the disclosure, a system for
differentiating whether a subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke, is
contemplated, comprising: [0073] a) an analyzer unit configured to
bringing a sample from a subject who suffers from ischemic stroke
into contact with a detection agent that specifically binds to the
marker cardiac Troponin for a time sufficient to allow for the
formation of a complex of the said detection agent and the marker
from the sample, [0074] b) an analyzer unit configured to measure
the amount of the formed complex, wherein the said amount of the
formed complex is proportional to the amount of the marker present
in the sample, [0075] c) a computing device having a processor and
in operable communication with said analysis units, and [0076] d) a
non-transient machine readable media including a plurality of
instructions executable by the processor, the instructions, when
executed transform the amount of the formed complex into an amount
of the marker reflecting the amount of the marker present in the
sample, compare said amount to a reference, and establish an aid
for differentiating whether a subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke based on
the result of said comparison to said reference.
[0077] Preferably, the system also comprises a detection agent that
specifically binds to natriuretic peptide.
[0078] A suitable detection agent may be, in an aspect, an antibody
which is specifically binds to the cardiac troponin, in a sample of
a subject to be investigated by the method of the disclosure.
Another detection agent that can be applied, in an aspect, may be
an aptamere which specifically binds to the marker in the sample.
In yet an aspect the, sample is removed from the complex formed
between the detection agent and the marker prior to the measurement
of the amount of formed complex. Accordingly, in an aspect, the
detection agent may be immobilized on a solid support. In yet an
aspect, the sample can be removed from the formed complex on the
solid support by applying a washing solution. The formed complex
shall be proportional to the amount of the marker present in the
sample. It will be understood that the specificity and/or
sensitivity of the detection agent to be applied defines the degree
of proportion of at least one marker comprised in the sample which
is capable of being specifically bound. Further details on how the
determination can be carried out are also found elsewhere herein.
The amount of formed complex shall be transformed into an amount of
the marker reflecting the amount indeed present in the sample. Such
an amount, in an aspect, may be essentially the amount present in
the sample or may be, in another aspect, an amount which is a
certain proportion thereof due to the relationship between the
formed complex and the amount present in the original sample.
[0079] In yet an aspect of the aforementioned method, step a) may
be carried out by an analyzer unit, in an aspect, an analyzer unit
as defined elsewhere herein.
[0080] In an aspect of the method of the disclosure, the amount
determined in step a) is compared to a reference. In an aspect, the
reference is a reference as defined elsewhere herein. In yet
another aspect, the reference takes into account the proportional
relationship between the measured amount of complex and the amount
present in the original sample. Thus, the references applied in an
aspect of the method of the disclosure are artificial references
which are adopted to reflect the limitations of the detection agent
that has been used. In another aspect, said relationship can be
also taken into account when carrying out the comparison, e.g., by
including a normalization and/or correction calculation step for
the determined amount prior to actually comparing the value of the
determined amount and the reference. Again, the normalization
and/or correction calculation step for the determined amount adopts
the comparison step such that the limitations of the detection
agent that has been used are reflected properly. In an aspect, the
comparison is carried out automatically, e.g., assisted by a
computer system or the like.
[0081] The aid for differentiating whether a subject suffers from
cardioembolic ischemic stroke or from non-cardioembolic ischemic
stroke is established based on the comparison carried out in step
b) by allocating the subject either (i) the group of subjects who
suffer from cardioembolic stroke or (ii) the group of who suffer
from non-cardioembolic stroke as set forth herein elsewhere. As
discussed elsewhere herein already, the allocation of the
investigated subject must not be correct in 100% of the
investigated cases. Moreover, the groups of subjects into which the
investigated subject is allocated are artificial groups in that
they are established based on statistical considerations, i.e. a
certain preselected degree of likelihood based on which the method
of the disclosure shall operate. In an aspect of the disclosure,
the aid for the differentiation is established automatically, e.g.,
assisted by a computing device or the like, as described and
disclosed herein.
[0082] In an aspect of the method of the disclosure, said method
further comprises a step of recommending and/or managing the
subject according to the result established in step c) as set forth
elsewhere herein in detail.
[0083] In an aspect of the aforementioned method, steps b) and/or
c) are carried out by one or more analyzer units as set forth
elsewhere herein.
[0084] Method for Diagnosing Atrial Fibrillation
[0085] Atrial fibrillation (AF) is frequently no recognised by the
patient. This is the case in approximately 40% of patients
indicating that history taking in insensitive for the diagnosis of
atrial fibrillation (Kamel H. et al, Curr Atheroscler Rep 2011: 13:
338-343). While these numbers relate to persistent atrial
fibrillation, paroxysmal atrial fibrillation is even more difficult
to diagnose and can only be captured by inpatient cardiac telemetry
or even Jolter Monitoring. The latter having the advantage, that
the ECG is recorded and can later on be reviewed by an experienced
physician. Using Holter ECG paroxysmal--previously unrecognised
atrial fibrillation was more frequent than persistent atrial
fribillation (Rizos T. et all. Cerebrovasc. Dis 2011: 32: 276-282).
In order to capture paroxysmal/ischmemic atrial fibrillation
reliably 72 h Holter monitoring appears necessary (Gumbinger C et
al, Europ. J of Neurology 2011 ahead of publication). Thus
recognition of paroxysmal atrial fibrillation is a significant
challenge, specifically as at least 1% of the general population
has persistent atrial fibrillation and the frequency increases with
age (Rizos T. et al).
[0086] The inventors have found that the determination of a cardiac
Troponin allows for diagnosing atrial fibrillation. Interestingly,
patients with intermittent AF had also increased cardiac Troponin
levels. Therefore, also patients exhibiting intermittent AF can be
identified by determining the amount of cardiac Troponin.
[0087] The definitions and explanations given herein above apply
mutatis mutandis to the following embodiments of the present
disclosure.
[0088] Moreover, the present disclosure relates to a method for
diagnosing atrial fibrillation in a subject suspected to suffer
from atrial fibrillation, comprising a) determining the amount of a
cardiac Troponin in a sample from said subject.
[0089] In a preferred embodiment the method comprises the further
step of [0090] b) comparing the, thus, determined amount of said
cardiac Troponin to a reference amount. Thereby, intermittent
atrial fibrillation is diagnosed.
[0091] Accordingly, the present disclosure relates to a method for
diagnosing atrial fibrillation in a subject suspected to suffer
from atrial fibrillation, comprising [0092] a) determining the
amount of a cardiac Troponin in a sample from said subject, and
[0093] b) comparing the, thus, determined amount of said cardiac
Troponin to a reference amount, whereby atrial fibrillation is
diagnosed.
[0094] Preferably, it is diagnosed whether a subject suffers from
atrial fibrillation, or not, by carrying out the further step c) of
diagnosing whether the subject suffers from atrial fibrillation, or
not.
[0095] Preferably, intermittent atrial fibrillation is
diagnosed.
[0096] Accordingly, the present disclosure, in particular relates
to a method for diagnosing intermittent atrial fibrillation in a
subject suspected to suffer from atrial fibrillation, comprising
[0097] a) determining the amount of a cardiac Troponin in a sample
from said subject, and [0098] b) comparing the, thus, determined
amount of said cardiac Troponin to a reference amount, whereby
intermittent atrial fibrillation is diagnosed.
[0099] In a preferred embodiment of the method of the present
disclosure, step a) further comprises the determination of the
amount of a natriuretic peptide in the sample from the subject.
Preferably, the, thus, determined amount of the natriuretic peptide
is compared in step b) to a reference amount for a natriuretic
peptide.
[0100] Thus, the present disclosure also relates to a method for
diagnosing atrial fibrillation in a subject suspected to suffer
from atrial fibrillation, comprising [0101] a) determining the
amount of a cardiac Troponin and of natriuretic peptide in a sample
from said subject, and [0102] b) comparing the amount of said
cardiac Troponin as determined in step a) to a reference amount for
the cardiac Troponin, and the amount of said natriuretic peptide to
a reference amount for the natriuretic peptide, whereby atrial
fibrillation is diagnosed.
[0103] The term "atrial fibrillation" is well known in the art.
Atrial fibrillation is e.g. reviewed by Fuster et al. which
herewith is incorporated by reference in its entire disclosure
content (Fuster V, Ryden L E, Asinger R W, et al. ACC/AHA/ESC
Guidelines for the Management of Patients With Atrial Fibrillation:
Executive Summary A Report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines and the European Society of Cardiology Committee for
Practice Guidelines and Policy Conferences (Committee to Develop
Guidelines for the Management of Patients With Atrial Fibrillation)
Developed in Collaboration With the North American Society of
Pacing and Electrophysiology. Circulation. Oct. 23, 2001;
104(17):2118-50). Atrial fibrillation is an abnormal heart rhythm
which involves the two upper chambers of the heart. In a normal
heart rhythm, the impulse generated by the sino-atrial node spreads
through the heart and causes contraction of the heart muscle and
pumping of blood. In atrial fibrillation, the regular electrical
impulses of the sino-atrial node are replaced by disorganized,
rapid electrical impulses which result in irregular heart
beats.
[0104] Atrial fibrillation (AF) can be permanent, persistent or
intermittent (for an explanation of these terms, see also Fuster et
al. (loc. cit.).
[0105] A subject, preferably, suffers from permanent AF, if the AF
has persisted for more than one year. In particular, conversion
back to sinus rhythm does not occur (or only if treated).
[0106] A subject, preferably, suffers from persistent AF, if the AF
lasts more than 7 days and may require either pharmacologic or
electrical intervention to terminate atrial fibrillation. Thus
persistent AF occurs in episodes, but the arrhythmia does not
convert back to sinus rhythm spontaneously.
[0107] A subject, preferably, suffers from intermittent AF
(frequently also referred to as paroxymal AF), if there are
episodes of atrial fibrillation that terminate spontaneously. The
episodes of atrial fibrillation may last from seconds to days.
Preferably, the episodes last less than one hour.
[0108] In the context of the aforementioned method, preferably,
intermittent atrial fibrillation is diagnosed.
[0109] Permanent and persistent atrial fibrillation can be easily
diagnosed, e.g., on an electrocardiogram. Characteristic findings
are, preferably, the absence of P waves, unorganized electrical
activity in their place, and irregularity of R-R interval due to
irregular conduction of impulses to the ventricles. Intermittent
atrial fibrillation is more difficult to diagnose, since a
diagnosis is only possible during the episode of atrial
fibrillation.
[0110] The inventors have surprisingly found that the determination
of a cardiac Troponin (and, optionally of natriuretic peptide) in a
sample of a subject suspected to suffer from atrial fibrillation
allows for the diagnosis of atrial fibrillation. In particular,
increased levels of a cardiac Troponin are indicative for a subject
suffering AF, whereas decreased levels of a cardiac Troponin are
indicative for a subject not suffering from AF. Further, the
determination of a cardiac Troponin also allows for the diagnosis
of intermittent AF, even in the absence of an episode of AF (at the
time point at which the sample is obtained). Thus, by carrying out
the aforementioned method, intermittent atrial fibrillation is,
preferably, diagnosed in the absence of an episode of atrial
fibrillation, in particular at the time point at which the sample
is obtained. Thus, the subject, preferably, does not suffer from an
episode of AF when the sample is obtained.
[0111] The subject in accordance with the aforementioned method of
the present disclosure shall be suspected to suffer from atrial
fibrillation. A subject suspected to suffer from atrial
fibrillation (e.g. from intermittent atrial fibrillation),
preferably, is a subject who has one or more risk factors of atrial
fibrillation. These risk factors are well known in the art and
include heart disease, including valve problems and a history of
heart attack and heart surgery, systemic hypertension, especially
if it's not well controlled with lifestyle changes or medications,
and alcohol consumption. Preferably, the subject being suspected to
belongs to a risk group. In particular, it is envisaged that the
subject is a subject with proven or suspected cardiac disorders
including subjects having risk factors predisposing to cardiac
disorders such as arterial or systemic hypertension, diabetes
mellitus, smokers, individuals with hyperlipemia or signs of the
metabolic syndrome, in particular if the subject is at advanced age
(more than 60, 65, 70 and preferably 75 years of age).
Alternatively, or additionally the subject may, preferably, suffer
from valvular disorders, preferably from mitral valve disorders. It
is further envisaged that the subject suspected to suffer from AF,
suffers from hyperthyroidism.
[0112] In some embodiments of the method of the present disclosure,
the subject who is suspected to suffer from atrial fibrillation,
preferably, suffers from ischemic stroke, in particular from
cardioembolic ischemic stroke (for an explanation of the these
terms, see elsewhere herein). If the subject to be tested in
accordance with the aforementioned method suffers from ischemic
stroke, the sample is, preferably, obtained immediately after the
onset of stroke symptoms as described in the context of the method
for early differentiating whether a subject suffers from
cardioembolic stroke or from non-cardioembolic ischemic stroke.
[0113] However, it is also preferred that the subject to be tested
does not suffer from ischemic stroke.
[0114] Preferably, the reference amount in connection with the
aforementioned method is derived from a subject known to suffer
from atrial fibrillation (or from a group of subjects), and wherein
an identical amount of the cardiac Troponin (and, optionally, of
the natriuretic peptide), or an amount of the cardiac Troponin
(and, optionally, of the natriuretic peptide)which is increased as
compared to the reference amount, indicates that the subject
suffers from atrial fibrillation. Additionally or alternatively,
the reference amount is derived from a subject known not to suffer
from atrial fibrillation or from a group of such subjects, wherein
an identical amount of the cardiac Troponin (and, optionally, of
the natriuretic peptide), or an amount of the cardiac troponin
Troponin (and, optionally, of the natriuretic peptide) which is
decreased as compared to the reference amount, indicates that the
subject does not suffer from atrial fibrillation.
[0115] Further, the reference amount may define a threshold amount
for the cardiac Troponin (and, optionally for the natriuretic
peptide), whereby an amount of Troponin (and, optionally of the
natriuretic peptide) in the sample of the test subject larger than
the respective threshold shall be indicative for atrial
fibrillation, while an amount of Troponin (and, optionally, of the
natriuretic peptide) in the sample of the test subject lower than
the respective threshold shall indicate that the subject does not
suffer from atrial fibrillation.
[0116] Exemplary reference amounts are indicated herein below.
[0117] A preferred reference amount indicating atrial fibrillation
is an amount of a cardiac troponin, in particular of Troponin T of
about 6 pg/ml to about 40 pg/ml and, more preferably, 8 to 30
pg/ml, or about 10 to about 20 pg/ml, even more preferably of about
15 to 20 pg/ml. Even more preferably, the reference is an amount of
about 10 pg/ml, or most preferably, about 7 pg/ml. A test amount
being essentially identical or increased shall be indicative for
atrial fibrillation while a decreased amount in the test sample as
compared to the reference amount shall indicate that the subject
does not suffer from atrial fibrillation. Preferably, the
aforementioned reference amounts are derived from a subject or a
group of subjects known to suffer from atrial fibrillation.
[0118] An exemplary reference amount indicating atrial fibrillation
is an amount of a natriuretic peptide, in particular, of NT-proBNP
of about 300 pg/ml to about 1500 pg/ml and, more preferably, 400 to
1300 pg/ml, even more preferably of about 500 to 1000 pg/ml. Even
more preferably, the reference is an amount of about 500, 400, or
most preferably, of about 300 pg/ml. A test amount being
essentially identical or increased shall be indicative for atrial
fibrillation while a decreased amount in the test sample as
compared to the reference amount shall indicate that the subject
does not suffer from atrial fibrillation. Preferably, the
aforementioned reference amounts are derived from a subject or a
group of subjects known to suffer from atrial fibrillation.
[0119] As set forth above, the diagnosis of intermittent atrial
fibrillation is challenging, whereas the diagnosis of permanent or
persistent atrial fibrillation is rather easy. Since subjects with
permanent and persistent atrial fibrillation can be identified
without further ado, it is of particular interest to identify those
subjects who do not suffer from permanent or persistent atrial
fibrillation, but who suffer from intermittent atrial
fibrillation.
[0120] Interestingly, it has been shown in the context of the
studies of the present disclosure, that the levels of cardiac
troponins and of natriuretic peptides are lower in subjects with
intermittent atrial fibrillation than in subjects with persistent
or permanent atrial fibrillation. This is advantageous, since the
determination of a cardiac Troponin and, optionally, a natriuretic
peptide allows to identify those patients who suffer from
intermittent fibrillation.
[0121] Therefore, in a preferred embodiment of the present
disclosure intermittent atrial fibrillation shall be diagnosed, in
particular in subject suspected to suffer from intermittent atrial
fibrillation.
[0122] In order to allow for the diagnosis of intermittent AF, the
amount of the cardiac Troponin, and, optionally, the amount of the
natriuretic peptide, as determined in step a) shall be compared in
step b) to two reference amounts. It is envisaged that a first
reference amount is derived from a subject known to suffer from
intermittent AF (or from a group of such subjects), and that a
second reference amount is derived from a subject known to suffer
from permanent or, in particular, from persistent AF (or from a
group of such subjects). Of course, the reference amounts shall be
derived from samples of the aforementioned subjects.
[0123] Preferably, an amount of the cardiac Troponin and,
optionally, of the natriuretic peptide in the sample of the test
subject which is essentially identical or larger than the than the
reference amount (for the cardiac Troponin and, optionally, for the
natriuretic peptide) derived from a subject known to suffer from
intermittent AF (or from a group of such subjects), but which is
lower than the reference amount derived from a subject known to
suffer from permanent or from persistent AF (or from a group of
such subjects) is indicative for the diagnosis of intermittent
AF.
[0124] A preferred reference amount for a cardiac Troponin, in
particular for Troponin T, derived from a subject known to suffer
from intermittent AF (or from a group of such subjects) is within a
range of about 5 to 10 pg/ml. Preferably, the reference amount is
about 9 pg/ml.
[0125] A preferred reference amount for a cardiac Troponin, in
particular for Troponin T, derived from a subject known to suffer
from permanent or from persistent AF (or from a group of such
subjects) is within a range of about 12 to 25 pg/ml. Preferably,
the reference amount is about 18 pg/ml.
[0126] A preferred reference amount for a natriuretic peptide, in
particular for NT-proBNP, derived from a subject known to suffer
from intermittent AF (or from a group of such subjects) is within a
range of about 300 to 500 pg/ml. Preferably, the reference amount
is about 350 pg/ml.
[0127] A preferred reference amount for a natriuretic peptide, in
particular for NT-proBNP, derived from a subject known to suffer
from permanent or from persistent AF (or from a group of such
subjects) is within a range of about 900 to 1500 pg/ml. Preferably,
the reference amount is about 900 pg/ml.
[0128] In another preferred embodiment of the method of diagnosing
AF, intermittent AF is diagnosed. The subject according to this
preferred embodiment shall be known not to suffer from permanent
and/or persistent atrial fibrillation (which can be determined
without further ado, see above).
[0129] Thus also envisaged is method for diagnosing intermittent
atrial fibrillation in a subject suspected to suffer from
intermittent atrial fibrillation, but known not to suffer from
persistent and/or permanent atrial fibrillation, comprising [0130]
a) determining the amount of a cardiac Troponin (and, optionally, a
natriuretic peptide) in a sample from said subject, and [0131] b)
comparing the, thus, determined amount of said cardiac Troponin
(and, optionally of said natriuretic peptide) to a reference amount
(s), whereby intermittent atrial fibrillation is diagnosed.
[0132] The subject suspected to suffer from intermittent AF,
preferably, has the same risk factors as the subject suspected to
suffer from AF (see elsewhere herein). In particular, it is
envisaged that the subject suffers from ischemic stroke, in
particular from cardioembolic ischemic stroke.
[0133] The reference amount to be applied in the context of the
present disclosure shall be derived from a subject known to suffer
from intermittent AF, or from a subject known not to suffer from
AF.
[0134] Preferably, the reference amount in connection with the
aforementioned embodiment is derived from a subject known to suffer
from intermittent atrial fibrillation (or from a group of
subjects), and wherein an identical amount of the cardiac Troponin
(and, optionally, of the natriuretic peptide), or an amount of the
cardiac Troponin (and, optionally, of the natriuretic peptide)which
is increased as compared to the reference amount, indicates that
the subject suffers intermittent atrial fibrillation. Additionally
or alternatively, the reference amount is derived from a subject
known not to suffer from atrial fibrillation, wherein an identical
amount of the cardiac Troponin (and, optionally, of the natriuretic
peptide), or an amount of the cardiac troponin Troponin (and,
optionally, of the natriuretic peptide) which is decreased as
compared to the reference amount, indicates that subject does not
suffer from intermittent atrial fibrillation.
[0135] A preferred reference amount indicating intermittent atrial
fibrillation is an amount of a cardiac troponin, in particular of
Troponin T of about 5 pg/ml to about 30 pg/ml and, more preferably,
5 to 25 pg/ml, or about 6 to about 10 pg/ml, even more preferably
of about 6 to 8 pg/ml. Even more preferably, the reference is an
amount of about 8 pg/ml, or most preferably, about 7 pg/ml. A test
amount being essentially identical or increased shall be indicative
for intermittent atrial fibrillation while a decreased amount in
the test sample as compared to the reference amount shall indicate
that the subject does not suffer from intermittent atrial
fibrillation. Preferably, the aforementioned reference amounts are
derived from a subject or a group of subjects known to suffer from
intermittent atrial fibrillation.
[0136] A preferred reference amount indicating intermittent atrial
fibrillation is an amount of a natriuretic peptide, in particular,
of NT-proBNP of about 300 pg/ml to about 800 pg/ml and, more
preferably, 300 to 700 pg/ml, even more preferably of about 350 to
500 pg/ml. Even more preferably, the reference is an amount of
about 500, 400, or most preferably, of about 300 pg/ml. A test
amount being essentially identical or increased shall be indicative
for intermittent atrial fibrillation while a decreased amount in
the test sample as compared to the reference amount shall indicate
that the subject does not suffer from intermittent atrial
fibrillation. Preferably, the aforementioned reference amounts are
derived from a subject or a group of subjects known to suffer from
intermittent atrial fibrillation.
[0137] In a preferred embodiment of the aforementioned method of
the present disclosure, said method further comprises recommending
a therapy for said subject, if the subject has been diagnosed to
suffer atrial fibrillation, in particular from intermittent atrial
fibrillation. Preferred therapies that can be recommended in a
subject who suffers from atrial fibrillation are, e.g., described
by Fuster et al. (Fuster et al. J Am Coll Cardiol 2001: 38: 1231,
and Fuster V. et al. Circulation 2006: 114 to 257). Preferred
therapies included, administration of beta blockers,
non-dihydropyridine calcium channel blockers, digoxin, vitamin K
antatgonists, aspirin, acetylsalicylic acid. Moreover,
pharmacologic or electrical intervention can be recommended to
terminate atrial fibrillation. Pharmacologic intervention,
preferably, include administration of flecainide, dofetilide,
propafenone and/or ibutilide. Further envisaged is the
administration of factor Xa inhibitors such as rivaroxoban and/or
dabigatran (see Patel M.R. et al, NEJM 2011: 365: 883-91; Connolly
S. J. et al NEJM 2010: 261: 1139-51).
Preferred Embodiments of the Aforementioned Method
[0138] Preferably, intermittent atrial fibrillation is
diagnosed.
[0139] In a preferred embodiment, the subject does not suffer from
ischemic stroke.
[0140] In another preferred embodiment, the subject suspected to
suffer from atrial fibrillation suffers from ischemic stroke, in
particular from cardioembolic stroke, and wherein the sample has
been obtained immediately after the onset of symptoms of ischemic
stroke. Preferably, the sample from said subject has been obtained
from said subject not more than 12 hours after the onset of
symptoms of ischemic stroke, in particular not more than 6 hours or
not more than 3 hours after the onset of symptoms of ischemic
stroke.
[0141] In a preferred embodiment, wherein the subject is known not
to suffer from persistent and/or permanent atrial fibrillation, in
particular, wherein the reference amount is derived from a subject
known to suffer from intermittent atrial fibrillation or from a
group of such subjects, and wherein an identical amount of the
cardiac Troponin, or an amount of the cardiac Troponin which is
increased as compared to the reference amount, indicates that the
subject suffers intermittent atrial fibrillation, and/or wherein
the reference amount is derived from a subject known not to suffer
from atrial fibrillation or from a group of such subjects, wherein
an identical amount of the cardiac Troponin, or an amount of the
cardiac troponin Troponin which is decreased as compared to the
reference amount, indicates that subject does not suffer from
intermittent atrial fibrillation.
[0142] In another preferred embodiment, the amount of the cardiac
Troponin in the sample from the subject is compared to two
reference amounts, wherein the first reference amount is derived
from a subject known to suffer from intermittent AF or from a group
of such subjects, and wherein the second reference amount is
derived from a subject known to suffer from permanent or from
persistent AF or from a group of such subjects. Preferably, an
amount of the cardiac Troponin in the sample of the subject which
is essentially identical or larger than the than the first
reference amount, but which is lower than the second reference
amount derived from a subject known to suffer from permanent or
from persistent AF is indicative for the diagnosis of intermittent
AF.
[0143] In a preferred embodiment, the method further comprises the
determination of the amount of a natriuretic peptide, in particular
of a brain natriuretic peptide, in particular of BNP and
NT-proBNP.
[0144] Preferably, intermittent atrial fibrillation is diagnosed in
the absence of an episode of atrial fibrillation, in particular at
the time point at which the sample is obtained.
[0145] In another aspect of the disclosure, a system for diagnosing
AF, in particular, intermittent AF, is contemplated, comprising:
[0146] a) an analyzer unit configured to bringing a sample from a
subject who is suspected to suffer from AF, in particular,
intermittent AF into contact with a detection agent that
specifically binds to the marker cardiac Troponin for a time
sufficient to allow for the formation of a complex of the said
detection agent and the marker from the sample, [0147] b) an
analyzer unit configured to measure the amount of the formed
complex, wherein the said amount of the formed complex is
proportional to the amount of the marker present in the sample,
[0148] c) a computing device having a processor and in operable
communication with said analysis units, and [0149] d) a
non-transient machine readable media including a plurality of
instructions executable by the processor, the instructions, when
executed transform the amount of the formed complex into an amount
of the marker reflecting the amount of the marker present in the
sample, compare said amount to a reference, and establish an aid
for diagnosing AF, in particular, intermittent AF based on the
result of said comparison to said reference.
[0150] Preferably, the system also comprises a detection agent that
specifically binds to natriuretic peptide.
[0151] In yet an aspect of the aforementioned method, step a) may
be carried out by an analyzer unit, in an aspect, an analyzer unit
as defined elsewhere herein.
[0152] In an aspect of the method of the disclosure, the amount
determined in step a) is compared to a reference. In an aspect, the
reference is a reference as defined elsewhere herein. In yet
another aspect, the reference takes into account the proportional
relationship between the measured amount of complex and the amount
present in the original sample. Thus, the references applied in an
aspect of the method of the disclosure are artificial references
which are adopted to reflect the limitations of the detection agent
that has been used. In another aspect, said relationship can be
also taken into account when carrying out the comparison, e.g., by
including a normalization and/or correction calculation step for
the determined amount prior to actually comparing the value of the
determined amount and the reference. Again, the normalization
and/or correction calculation step for the determined amount adopts
the comparison step such that the limitations of the detection
agent that has been used are reflected properly. In an aspect, the
comparison is carried out automatically, e.g., assisted by a
computer system or the like.
[0153] The aid for diagnosing AF, in particular, intermittent AF is
established based on the comparison carried out in step b) by
allocating the subject either (i) the group of subjects who suffer
from AF or (ii) the group of who do not suffer from AF as set forth
herein elsewhere. As discussed elsewhere herein already, the
allocation of the investigated subject must not be correct in 100%
of the investigated cases. Moreover, the groups of subjects into
which the investigated subject is allocated are artificial groups
in that they are established based on statistical considerations,
i.e. a certain preselected degree of likelihood based on which the
method of the disclosure shall operate. In an aspect of the
disclosure, the aid for optimizing a risk assessment is established
automatically, e.g., assisted by a computing device or the like, as
described and disclosed herein.
[0154] In an aspect of the method of the disclosure, said method
further comprises a step of recommending and/or managing the
subject according to the result established in step c) as set forth
elsewhere herein in detail.
[0155] In an aspect of the aforementioned method, steps b) and/or
c) are carried out by one or more analyzer units as set forth
elsewhere herein.
[0156] Moreover, the present disclosure relates to the use of a
cardiac Troponin and/or of a detection agent, which specifically
binds thereto (and optionally of a natriuretic peptide and/or of
detection agent, which specifically binds thereto) in a sample of a
subject suffering from ischemic stroke for early differentiating
whether the subject suffers from cardioembolic ischemic stroke or
from non-cardioembolic ischemic stroke, wherein the sample has been
obtained immediately after the onset of symptoms of ischemic
stroke. Preferably, said sample has been obtained not more than 6
hours after the onset of symptoms of stroke.
[0157] Also envisaged by the present disclosure is the use of a
cardiac Troponin and/or of a detection agent, which specifically
binds thereto (and optionally of a natriuretic peptide and/or of
detection agent, which specifically binds thereto) in a sample of a
subject suspected to suffer from atrial fibrillation for diagnosing
atrial fibrillation in a said subject. Preferably, intermittent
atrial fibrillation is diagnosed.
[0158] The term "detection agent" as used herein refers to an agent
which is capable of specifically recognizing and binding the
biomarker referred to herein (a cardiac Troponin, or a natriuretic
peptide) when present in a sample. Moreover, said agent shall allow
for direct or indirect detection of the complex formed by the said
agent and the biomarker. Direct detection can be achieved by
including into the agent a detectable label. Indirect labelling may
be achieved by a further agent which specifically binds to the
complex comprising the biomarker and the detection agent wherein
the said further agent is than capable of generating a detectable
signal. Suitable compounds which can be used as detection agents
are well known in the art. Preferably, the detection agent is an
antibody or aptamere which specifically binds to the biomarker.
Antibodies as referred to herein include both polyclonal and
monoclonal antibodies, as well as fragments thereof, such as Fv,
Fab and F(ab).sub.2 fragments that are capable of binding antigen
or hapten. Also envisaged are single chain antibodies and humanized
hybrid antibodies wherein amino acid sequences of a non-human donor
antibody exhibiting a desired antigen-specificity are combined with
sequences of a human acceptor antibody.
[0159] The present disclosure further relates to a device for early
differentiating whether a subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke in a
subject suffering from ischemic stroke, said device comprising:
[0160] a) an analyzing unit (or an analyzer unit) comprising a
detection agent for a cardiac Troponin which allows for the
determination of the amount of said cardiac Troponin (and,
optionally, a detection agent for a natriuretic peptide which
allows for the determination of the amount of said natriuretic
peptide); and [0161] b) an evaluation unit (or an analyzer unit)
comprising a data processor having implemented an algorithm for
comparing the amount(s) determined by the analyzing unit with
reference amount(s) stored in a database in order to differentiate
whether a subject suffers from cardioembolic ischemic stroke or
from non-cardioembolic ischemic stroke, wherein the reference
amount is derived from a sample from a reference subject as
described herein elsewhere in the context of the method for
differentiating whether a subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke, and the
algorithm is an algorithm as defined in the context of the said
method.
[0162] The present disclosure further relates to a device for
diagnosing atrial fibrillation, in particular, intermittent atrial
fibrillation in a subject suspected to suffer from atrial
fibrillation, said device comprising: [0163] a) an analyzing unit
(or an analyzer unit)comprising a detection agent for a cardiac
Troponin which allows for the determination of the amount of said
cardiac Troponin (and, optionally, a detection agent for a
natriuretic peptide which allows for the determination of the
amount of said natriuretic peptide); and [0164] b) an evaluation
unit (or an analyzer unit) comprising a data processor having
implemented an algorithm for comparing the amount(s) determined by
the analyzing unit with reference amount(s) stored in a database in
order to diagnose atrial fibrillation, in particular intermittent
atrial fibrillation, wherein the reference amount is derived from a
sample from a reference subject as described herein elsewhere in
the context of the method for diagnosing atrial fibrillation (in
particular, intermittent atrial fibrillation), and the algorithm is
an algorithm as defined in the context of the method for diagnosing
atrial fibrillation (in particular atrial fibrillation).
[0165] The term "device" as used herein relates to a system
comprising the aforementioned units operatively linked to each
other as to allow the diagnosis according to the methods of the
disclosure. Preferred detection agents which can be used for the
analyzing unit are disclosed elsewhere herein. The analyzing unit,
preferably, comprises said detection agents in immobilized form on
a solid support which is to be contacted to the sample comprising
the biomarkers the amount of which is to be determined. Moreover,
the analyzing unit can also comprise a detector which determines
the amount of detection agent which is specifically bound to the
biomarker(s). The determined amount can be transmitted to the
evaluation unit. Said evaluation unit comprises a data processing
element, such as a computer, with an implemented algorithm for
carrying out a comparison between the determined amount and a
suitable reference. Suitable references can be derived from samples
of subjects to be used for the generation of reference amounts as
described elsewhere herein above. The diagnostic results may be
given as output of parametric diagnostic raw data, preferably, as
absolute or relative amounts. It is to be understood that these
data may need interpretation by the clinician. However, also
envisage are expert system devices wherein the output comprises
processed diagnostic raw data the interpretation of which does not
require a specialized clinician. Preferably, the device of the
present disclosure can be used to carry out the aforementioned
method of the present disclosure in an automated manner.
[0166] A preferred embodiment of the instant disclosure includes a
system for guiding exercise as set forth herein. Examples of
systems include clinical chemistry analyzers, coagulation chemistry
analyzers, immunochemistry analyzers, urine analyzers, nucleic acid
analyzers, used to detect the result of chemical or biological
reactions or to monitor the progress of chemical or biological
reactions. More specifically, exemplary systems of the instant
disclosure may include Roche Elecsys.TM. Systems and Cobas.RTM. e
Immunoassay Analyzers, Abbott Architect.TM. and Axsym.TM.
Analyzers, Siemens Centaur.TM. and Immulite.TM. Analyzers, and
Beckman Coulter UniCel.TM. and Acess.TM. Analyzers, or the
like.
[0167] Embodiments of the system may include one or more analyzer
units utilized for practicing the subject disclosure. The analyzer
units of the system disclosed herein are in operable communication
with the computing device disclosed herein through any of a wired
connection, Bluetooth, LANS, or wireless signal, as are known.
Additionally, according to the instant disclosure, an analyzer unit
may comprise a stand-alone apparatus, or module within a larger
instrument, which performs one or both of the detection, e.g.
qualitative and/or quantitative evaluation of samples for
diagnostic purpose. For example, an analyzer unit may perform or
assist with the pipetting, dosing, mixing of samples and/or
reagents. An analyzer unit may comprise a reagent holding unit for
holding reagents to perform the assays. Reagents may be arranged
for example in the form of containers or cassettes containing
individual reagents or group of reagents, placed in appropriate
receptacles or positions within a storage compartment or conveyor.
Detection reagents may also be in immobilized form on a solid
support which are contacted with the sample.Further, an analyzer
unit may include a process and/or detection component which is
optimizable for specific analysis.
[0168] According to some embodiments, an analyzer unit may be
configured for optical detection of an analyte, for example a
marker, with a sample. An exemplary analyzer unit configured for
optical detection comprises a device configured for converting
electro-magnetic energy into an electrical signal, which includes
both single and multi-element or array optical detectors. According
to the present disclosure, an optical detector is capable of
monitoring an optical electro-magnetic signal and providing an
electrical outlet signal or response signal relative to a baseline
signal indicative of the presence and/or concentration of an
analyte in a sample being located in an optical path. Such devices
may also include, for example, photodiodes, including avalanche
photodiodes, phototransistors, photoconductive detectors, linear
sensor arrays, CCD detectors, CMOS detectors, including CMOS array
detectors, photomultipliers, and photomultiplier arrays. According
to certain embodiments, an optical detector, such as a photodiode
or photomultiplier, may contain additional signal conditioning or
processing electronics. For example, an optical detector may
include at least one pre-amplifier, electronic filter, or
integrated circuit. Suitable pre-preamplifiers include, for
example, integrating, transimpedance, and current gain (current
mirror) pre-amplifiers.
[0169] Additionally, one or more analyzer unit according to the
instant disclosure may comprise a light source for emitting light.
For example, a light source of an analyzer unit may consist of at
least one light emitting element (such as a light emitting diode,
an electric powered radiation source such as an incandescent lamp,
an electroluminescent lamp, a gas discharge lamp, a high-intensity
discharge lamp, a laser) for measuring analyte concentrations with
a sample being tested or for enabling an energy transfer (for
example, through florescent resonance energy transfer or catalyzing
an enzyme).
[0170] Further, an analyzer unit of the system may include one or
more incubation units (for example, for maintaining a sample or a
reagent at a specified temperature or temperature range). In some
embodiments, an analyzer unit may include a thermocycler, include a
real-time thermocycler, for subjecting a sample to repeated
temperature cycles and monitoring a change in the amount of an
amplification product with the sample.
[0171] Additionally, an analyzer unit of the system disclosed
herein may comprise, or be operationally connected to, a reaction
vessel or cuvette feeding unit. Exemplary feeding units include
liquid processing units, such as a pipetting unit, to deliver
samples and/or reagents to the reaction vessels. The pipetting unit
may comprise a reusable washable needle, e.g. a steel needle, or
disposable pipette tips. The analyzer unit may further comprise one
or more mixing units, for example a shaker to shake a cuvette
comprising a liquid, or a mixing paddle to mix liquids in a
cuvette, or reagent container.
[0172] It follows from the above that according to some embodiments
of the instant disclosure, portions of some steps of methods
disclosed and described herein may be performed by a computing
device. A computing device may be a general purpose computer or a
portable computing device, for example. It should also be
understood that multiple computing devices may be used together,
such as over a network or other methods of transferring data, for
performing one or more steps of the methods disclosed herein.
Exemplary computing devices include desktop computers, laptop
computers, personal data assistants ("PDA"), such as BLACKBERRY
brand devices, cellular devices, tablet computers, servers, and the
like. In general, a computing device comprises a processor capable
of executing a plurality of instructions (such as a program of
software).
[0173] A computing device has access to a memory. A memory is a
computer readable medium and may comprise a single storage device
or multiple storage devices, located either locally with the
computing device or accessible to the computing device across a
network, for example. Computer-readable media may be any available
media that can be accessed by the computing device and includes
both volatile and non-volatile media. Further, computer
readable-media may be one or both of removable and non-removable
media. By way of example, and not limitation, computer-readable
media may comprise computer storage media. Exemplary computer
storage media includes, but is not limited to, RAM, ROM, EEPROM,
flash memory or any other memory technology, CD-ROM, Digital
Versatile Disk (DVD) or other optical disk storage, magnetic
cassettes, magnetic tape, magnetic disk storage or other magnetic
storage devices, or any other medium which can be used for storing
a plurality of instructions capable of being accessed by the
computing device and executed by the processor of the computing
device.
[0174] According to embodiments of the instant disclosure, software
may include instructions which, when executed by a processor of the
computing device, may perform one or more steps of the methods
disclosed herein. Some of the instructions may be adapted to
produce signals that control operation of other machines and thus
may operate through those control signals to transform materials
far removed from the computer itself. These descriptions and
representations are the means used by those skilled in the art of
data processing, for example, to most effectively convey the
substance of their work to others skilled in the art.
[0175] The plurality of instructions may also comprise an algorithm
which is generally conceived to be a self-consistent sequence of
steps leading to a desired result. These steps are those requiring
physical manipulations of physical quantities.
[0176] Usually, though not necessarily, these quantities take the
form of electrical or magnetic pulses or signals capable of being
stored, transferred, transformed, combined, compared, and otherwise
manipulated. It proves convenient at times, principally for reasons
of common usage, to refer to these signals as values, characters,
display data, numbers, or the like as a reference to the physical
items or manifestations in which such signals are embodied or
expressed. It should be borne in mind, however, that all of these
and similar terms are to be associated with the appropriate
physical quantities and are merely used here as convenient labels
applied to these quantities. According to some embodiments of the
instant disclosure, an algorithm for carrying out a comparison
between a determined amount of one or more markers disclosed
herein, and a suitable reference, is embodied and performed by
executing the instructions. The results may be given as output of
parametric diagnostic raw data or as absolute or relative amounts.
According to various embodiments of the system disclosed herein, a
"diagnosis" may be provided by the computing device of a system
disclosed herein based on said comparison of the calculated
"amount" to a reference or a threshold. For example, a computing
device of a system may provide an indicator, in the form of a word,
symbol, or numerical value which is indicative of a particular
diagnosis.
[0177] The computing device may also have access to an output
device. Exemplary output devices include fax machines, displays,
printers, and files, for example. According to some embodiments of
the present disclosure, a computing device may perform one or more
steps of a method disclosed herein, and thereafter provide an
output, via an output device, relating to a result, indication,
ratio or other factor of the method.
[0178] The present disclosure further encompasses a kit for early
differentiating whether a subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke in a
subject suffers from ischemic stroke, said kit comprising a
detection agent for a cardiac Troponin and a standard (standards)
which reflects the reference amount(s) as derived from a sample
from a subject known suffer from cardioembolic stroke and/or from a
subject known to suffer from non-cardioembolic stroke.
[0179] The present disclosure, finally, encompasses a kit for
diagnosing atrial fibrillation in a subject suspected to suffer
from atrial fibrillation, said kit comprising a detection agent for
a cardiac Troponin (and, optionally, for a natriuretic peptide) and
a standard (standards) which reflects the reference amount(s) as
derived from a sample from a subject known suffer from atrial
fibrillation and/or from a subject known not to suffer from atrial
fibrillation.
[0180] The term "kit" as used herein refers to a collection of the
aforementioned components, preferably, provided in separately or
within a single container. The container also comprises
instructions for carrying out the method of the present disclosure.
These instructions may be in the form of a manual or may be
provided by a computer program code which is capable of carrying
out the comparisons referred to in the methods of the present
disclosure and to establish a diagnosis accordingly when
implemented on a computer or a data processing device. The computer
program code may be provided on a data storage medium or device
such as a optical storage medium (e.g., a Compact Disc) or directly
on a computer or data processing device. Moreover, the kit may,
preferably, comprise standards which reflect the reference amounts
as described and referred to elsewhere herein in detail. The
detection agent is, preferably, immobilized on a carrier, and,
preferably, a test stripe
[0181] The following examples, sequence listing, and figures are
provided for the purpose of demonstrating various embodiments of
the instant disclosure and aiding in an understanding of the
present disclosure, the true scope of which is set forth in the
appended claims. These examples are not intended to, and should not
be understood as, limiting the scope or spirit of the instant
disclosure in any way. It should also be understood that
modifications can be made in the procedures set forth without
departing from the spirit of the disclosure.
Illustrative Embodiments
[0182] The following comprises a list of illustrative embodiments
according to the instant disclosure which represent various
embodiments of the instant disclosure. These illustrative
embodiments are not intended to be exhaustive or limit the
disclosure to the precise forms disclosed, but rather, these
illustrative embodiments are provided to aide in further describing
the instant disclosure so that others skilled in the art may
utilize their teachings. [0183] 1. A method for early
differentiating whether a subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke,
comprising determining the amount of a cardiac Troponin in a sample
from a subject suffering from ischemic stroke, wherein the sample
has been obtained not more than 6 hours after the onset of symptoms
of ischemic stroke. [0184] 2. The method of embodiment 1, further
comprising the step of comparing the amount of said cardiac
Troponin to a reference amount, thereby differentiating whether
said subject suffers from cardioembolic stroke or from
non-cardioembolic ischemic stroke. [0185] 3. The method of
embodiments 1 and 2, wherein the sample been obtained from said
subject not more than 3 hours after the onset of symptoms of
ischemic stroke. [0186] 4. The method of any one of embodiments 1
to 3, wherein the reference amount is derived from a subject known
to suffer from cardioembolic stroke, and wherein an identical
amount of the cardiac Troponin, or an amount of the cardiac
troponin which is increased as compared to the reference amount,
indicates that the subject suffers from cardioembolic stroke,
and/or [0187] wherein the reference amount is derived from a
subject known to suffer from non- cardioembolic ischemic stroke,
and wherein an identical amount of the cardiac Troponin, or an
amount of the cardiac troponin which is decreased as compared to
the reference amount, indicates that the subject suffers from
non-cardioembolic ischemic stroke. [0188] 5. The method of any one
of embodiments 1 to 5, further comprising the determination of the
amount of a natriuretic peptide, in particular of a brain
natriuretic peptide, in particular of BNP or NT-proBNP. [0189] 6.
Use of a cardiac Troponin and/or of a detection agent, which
specifically binds thereto in a sample of a subject for early
differentiating whether the subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke, wherein
the sample has been obtained not later than 6 hours after the onset
of symptoms of ischemic stroke. [0190] 7. A device for early
differentiating whether a subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke in a
subject suffering from ischemic stroke, said device comprising:
[0191] a) an analyzing unit comprising a detection agent for a
cardiac Troponin which allows for the determination of the amount
of said cardiac Troponin (and, optionally, a detection agent for a
natriuretic peptide which allows for the determination of the
amount of said natriuretic peptide); and [0192] b) an evaluation
unit comprising a data processor having implemented an algorithm
for comparing the amount(s) determined by the analyzing unit with
reference amount(s) stored in a database in order to differentiate
whether a subject suffers from cardioembolic ischemic stroke or
from non-cardioembolic ischemic stroke, wherein the reference
amount is derived from a sample from a subject known to suffer from
cardioembolic stroke and/or from a sample from a subject known to
suffer from non-cardioembolic ischemic stroke, wherein said sample
has been obtained not more than 6 hours after the onset of symptoms
of ischemic stroke, and wherein the algorithm is as follows: [0193]
i) an identical amount of the cardiac Troponin, or an amount of the
cardiac troponin which is increased as compared to the reference
amount, is indicative for a subject suffers from cardioembolic
stroke, if the reference amount is derived from a subject known to
suffer from cardioembolic stroke, and/or [0194] ii) an identical
amount of the cardiac Troponin, or an amount of the cardiac
troponin which is decreased as compared to the reference amount, is
indicative for a subject who suffers from non-cardioembolic
ischemic stroke, if the reference amount is derived from a subject
known to suffer from non-cardioembolic ischemic stroke. [0195] 8. A
method for diagnosing intermittent atrial fibrillation in a human
subject suspected to suffer from atrial fibrillation, comprising
determining the amount of a cardiac Troponin in a sample from said
subject. [0196] 9. The method of embodiment 8, further comprising
the step of comparing the amount of the cardiac Troponin to a
reference amount. [0197] 10. The method of embodiments 8 and 9,
wherein the subject does not suffer from ischemic stroke. [0198]
11. The method of embodiments 8 and 9, wherein the subject
suspected to suffer from atrial fibrillation suffers from ischemic
stroke, in particular from cardioembolic stroke, and wherein the
sample has been obtained immediately after the onset of symptoms of
ischemic stroke. [0199] 12. The method of embodiment 11, wherein
said sample from said subject has been obtained from said subject
not more than 12 hours after the onset of symptoms of ischemic
stroke, in particular not more than 6 hours or not more than 3
hours after the onset of symptoms of ischemic stroke. [0200] 13.
The method of embodiments 8 to 12, wherein the subject is known not
to suffer from persistent and permanent atrial fibrillation. [0201]
14. The method of embodiment 13, wherein the reference amount is
derived from a subject known to suffer from intermittent atrial
fibrillation or from a group of such subjects, and wherein an
identical amount of the cardiac Troponin, or an amount of the
cardiac Troponin which is increased as compared to the reference
amount, indicates that the subject suffers intermittent atrial
fibrillation, and/or wherein the reference amount is derived from a
subject known not to suffer from atrial fibrillation or from a
group of such subjects, wherein an identical amount of the cardiac
Troponin, or an amount of the cardiac troponin Troponin which is
decreased as compared to the reference amount, indicates that
subject does not suffer from intermittent atrial fibrillation.
[0202] 15. The method of embodiments 9 to 12, wherein the amount of
the cardiac Troponin in the sample from the subject is compared to
two reference amounts, wherein the first reference amount is
derived from a subject known to suffer from intermittent AF or from
a group of such subjects, and wherein the second reference amount
is derived from a subject known to suffer from permanent or from
persistent AF or from a group of such subjects. [0203] 16. The
method of embodiment 15, wherein an amount of the cardiac Troponin
in the sample of the subject which is essentially identical or
larger than the than the first reference amount, but which is lower
than the second reference amount derived from a subject known to
suffer from permanent or from persistent AF is indicative for the
diagnosis of intermittent AF. [0204] 17. The method of any one of
embodiments 8 to 16, further comprising the determination of the
amount of a natriuretic peptide, in particular of a brain
natriuretic peptide, in particular of BNP and NT-proBNP. [0205] 18.
The method of any one of embodiments 8 to 17, wherein intermittent
atrial fibrillation is diagnosed in the absence of an episode of
atrial fibrillation, in particular at the time point at which the
sample is obtained. [0206] 19. Use of a cardiac Troponin and/or of
a detection agent, which specifically binds thereto in a sample of
a subject for early differentiating whether the subject suffers
from cardioembolic ischemic stroke or from non-cardioembolic
ischemic stroke, wherein the sample has been obtained not later
than 6 hours after the onset of symptoms of ischemic stroke. [0207]
20. Use of a cardiac Troponin and/or of a detection agent, which
specifically binds thereto in a sample of a human subject suspected
to suffer from atrial fibrillation for diagnosing intermittent
atrial fibrillation in a said subject. [0208] 21. A device for
early differentiating whether a subject suffers from cardioembolic
ischemic stroke or from non-cardioembolic ischemic stroke in a
subject suffering from ischemic stroke, said device comprising:
[0209] a) an analyzing unit comprising a detection agent for a
cardiac Troponin which allows for the determination of the amount
of said cardiac Troponin (and, optionally, a detection agent for a
natriuretic peptide which allows for the determination of the
amount of said natriuretic peptide); and [0210] b) an evaluation
unit comprising a data processor having implemented an algorithm
for comparing the amount(s) determined by the analyzing unit with
reference amount(s) stored in a database in order to differentiate
whether a subject suffers from cardioembolic ischemic stroke or
from non-cardioembolic ischemic stroke, wherein the reference
amount is derived from a sample from a subject defined in
embodiment 4, and the algorithm is an algorithm as defined in
embodiment 4. [0211] 22. A device for diagnosing intermittent
atrial fibrillation in a subject suspected to suffer from atrial
fibrillation, said device comprising: [0212] a) an analyzing unit
comprising a detection agent for a cardiac Troponin which allows
for the determination of the amount of said cardiac Troponin; and
[0213] b) an evaluation unit comprising a data processor having
implemented an algorithm for comparing the amount determined by the
analyzing unit with a reference amount (or reference amounts)
stored in a database in order to diagnose intermittent atrial
fibrillation, wherein the reference amount is derived from a sample
from a reference subject as defined in embodiment 14 or 15, and the
algorithm is an algorithm as defined in embodiment 14 or 16.
EXAMPLES
Example 1
Determination of Troponin T, GDF-15 and NT-proBNP
[0214] Troponin T was determined using Roche's
electrochemiluminescence ELISA sandwich test Elecsys Troponin T hs
(high sensitive) STAT (Short Turn Around Time) assay. The test
employs two monoclonal antibodies specifically directed against
human cardiac troponin T. The antibodies recognize two epitopes
(amino acid position 125-131 and 136-147) located in the central
part of the cardiac troponin T protein, which consists of 288 amino
acids (analytical sensitivity below 1.0).
[0215] NT-proBNP was determined using Roche's
electrochemiluminescence ELISA sandwich test Elecsys proBNP II STAT
(Short Turn Around Time) assay. The test employs two monoclonal
antibodies which recognize epitopes located in the N-terminal part
(1-76) of proBNP (1-108).
[0216] To determine the concentration of GDF-15 in serum and plasma
samples, an Elecsys prototype test was employed, using a
polyclonal, GDF-15 affinity chromatography-purified, goat
anti-human GDF-15 IgG antibody from R&D Systems (AF957). In
each experiment, a standard curve was generated with recombinant
human GDF-15 from R&D Systems (957-GD/CF). The results with new
batches or recombinant GDF-15 protein were tested in standard
plasma samples and any deviation above 10% was corrected by
introducing an adjustment factor for this assay. GDF-15
measurements in serum and plasma samples from the same patient
yielded virtually identical results after correction for eventual
dilution factors. The detection limit of the assay was 200
pg/ml.
Example 2
Patient Cohort
[0217] A total of 255 patients with ischemic stroke (mean age 70
years) were tested for NT pro BNP, trponinT and GDF 15. Transitory
ischemic attack was present in 23 patients, minor stroke was
diagnosed in 61 patients and major stroke was found in 108
patients. In addition as described above caotoid and transcranial
ultrasound as well as electro- and echocardiography were performed
and the patients were classified according to the TOAST criteria.
Moreover a 7 day HOLTER ECG was performed to identify unnoticed
atrial fibrillation on the routine electrocardiogram.
Example 3
Results
[0218] The following results were obtained (indicated are the
median values, the 25. percentile and the 75. percentile):
TABLE-US-00001 Troponin T NT-pro BNP GDF 15 pg/ml pg/ml pg/ml Large
Artery stenosis 4.9 262 1146 N = 46 0.0-16.3 110-611 801-1404
Cardioembolic stroke 11.6 868 1393 N = 66 3.8-29 365-1863 1005-2481
Small vessel 6.3 222 1188 N = 32 0.0-9.3 79-412 822-2025
Undetermined 5.3 152 1106 N = 97 0.0-10.8 63-371 805-1522
[0219] As previously described cardioembolic stroke was associated
with increased NT-pro BNP levels, GDF 15 did not contribute
significantly to stroke classification, however sensitive troponin
T did and thereby excluding the difficulties of separating cardiac
and brain B type natriuretic peptides.
[0220] These data are further supported by the classification
related to the presence of absence of atrial fibrillation. The
results are as follows:
TABLE-US-00002 Troponin T NT-pro BNP GDF 15 Pg/ml pg/ml pg/ml
Atrial fibrillation 15.8 1773 2220 N = 44 8-35 996-2667 1288-3069
Intermittent AF 9.2 448 1364 N = 28 4.9-24 321-802 1120-2214 No AF
4.3 137 1069 N = 101 0-10.6 62-386 765-1480
[0221] These data again demonstrate the association of AF with
NT-pro BNP and tropinin T but to a much lower extent with GDF 15.
The limitations of NT-pro BNP to be used in the classification were
also supported by the fact that median NT-pro BNP levels increased
from presentation (331 pg/ml) to 24 h follow up to 437 pg/ml, which
is in the range of 30% increase. To what extent this increase was
due to cardiac causes or released from the brain is not clear. In
contrast, there was no significant increase of Troponin T in the
follow-up. Thus, Troponin T levels remained stable.
[0222] In summary troponin T was found to be a powerful tool in the
identification/separation of causes of stroke. This method can also
be used in stroke prevention in combination with B type natriuretic
peptides. GDF 15 provided surprisingly little additional
information to this important clinical question.
Example 4
Case Studies
[0223] A 68 year old male is diagnosed with TIA (transient
ischmemic attack) based on clinical symptoms and a subsequent MRI.
His ECG is normal. His troponin T is 10.2 pg/ml, his NT-pro BNP is
520 pg/ml. An echocardiogram shown mild left ventricular
dysfunction, in the atria there was no thrombus formation. Based on
the TOAST criteria, the subject diagnosed as cardioembolic stroke
after ruling out other possibilities. Because of the intraatrial
thrombus formation he receives a Holter ECG for 3 days which
reveals paroxysmal atrial fibrillation. He is then places on
anticoagulant therapy as he had no contraindications.
[0224] A 72 year old male presents with minor stroke confirmed by
MRI after ruling out intracerebral bleeding by CT scan. His
Troponin T is 4.1 pg/ml and his NT-pro BNP is 245 pg/ml. A Carotis
ultrasound reveals a 80% stenosis of the right carotis fork. ECG
and echocardiography are normal, except minor diastolic
dysfunction. As he is unlikely to have AF a Holter ECG was not
carried out. He is advised to consider revision of the obstructed
carotis after more intense evaluation of intra- and extracerebral
arteries.
[0225] A 52 year old female reports dizzyness and palpitations and
visits the emergency room. Her Troponin T is 3 pg/ml, NT-pro BNP is
115 pg/ml, the ECG and the echocardiography are within normal.
Because symptoms do not direct to a cerebral event or atrial
fibrillation no further investigations were done which is in
concordance with the troponin T and NT-pro BNP results. She was
discharged with a suspected anxiety syndrome.
[0226] A 58 year male presents to the emergency room because of
temporary weakness of his left arm. His ECG is normal, his Troponin
T is 11.1 pg/ml and NT-pro BNP is 435 pg/ml. A MRI rules out
stroke, because of the Troponin T and NT-pro BNP results a Holter
ECG was later performed which revealed paroxysmal AF. A subsequent
Echo including TTE revealed intraatrial thrombi. He is diagnosed
with paroxysmal atrial fibrillation and put on anticoagulant
therapy with no obvious contraindications.
[0227] A 58 year old male presents with an ischemic stroke 2 hours
after start of symptoms to the emergency room, symptoms include
sudden weakness of the right arm and leg, his Troponin T is 12.5
pg/ml and NT-pro BNP is 920 pg/ml. Suspected cardioembolic stroke
is confirmed by esophageal echocardiography with a visible thrombus
in the left atrium. Angiography associated with lysis therapy
confirmed the diagnosis. Lysis therapy was successful and symptoms
improved, the patient is placed on anticoagulants.
[0228] A 58 year old male presents with dizzyness to his doctor, he
had diabetes mellitus for the past 8 years and he had smoked for
the most time in this life, arterial hypertension was known for the
past 10 years. Imaging excludes TIA, on echocardiography he has a
dilatated left atrium without thrombus formation, at presentation
his ECG is normal and sinus rhythm was recorded. His troponin is 11
pg/ml, NT-pro BNP is 480 pg/ml. A few weeks later, the patient is
put on Holter ECG and intermittent atrial fibrillation is
recorded.
CONCLUSIONS
[0229] The identification of stroke patients with cardioembolic
stroke is of importance as it directs further diagnostic steps and
treatment and even more importantly the prevention of future
strokes. Natriuretic peptides have shown usefulness in detecting
candidates for cardioembolic stroke in patients presenting with
ischemic stroke. However, as shown here natriuretic peptides may
change during the course of stroke limiting their diagnostic
potential, this is not the case with troponin T which is not
subject to substantial change.
[0230] A similar reasoning applies to the detection of paroxymal or
intermittent atrial fibrillation. Atrial fibrillation is more
frequent in the elderly population. Since diagnostic methods
(Holter ECG and detections methods for resulting atrial thrombi,
TEE) are of limited availability patient selection (rule in/rule
out) is important. This can be achieved by the determination of
troponin T (and NT-pro BNP) and the use of appropriate cut
offs.
[0231] In conclusion the inventors have identified troponin T as an
important diagnostic method in ischemic stroke as well as in
intermittent atrial fibrillation in order to direct further
diagnostic methods and treatment schedules
[0232] All references cited in this specification are herewith
incorporated by reference with respect to their entire disclosure
content and the disclosure content specifically mentioned in this
specification.
[0233] While this disclosure has been described as having an
exemplary design, the present disclosure may be further modified
within the spirit and scope of this disclosure. This application is
therefore intended to cover any variations, uses, or adaptations of
the disclosure using its general principles. Further, this
application is intended to cover such departures from the present
disclosure as come within the known or customary practice in the
art to which this disclosure pertains.
* * * * *